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A physiologically based pharmacokinetic (PBPK) model was developed that provides a
comprehensive description of the kinetics of trichloroethylene (TCE) and its metabolites,
trichloroethanol (TCOH), trichloroacetic acid (TCA), and dichloroacetic acid (DCA), in the mouse, rat,
and human for both oral and inhalation exposure. The model includes descriptions of the three
principal target tissues for cancer identified in animal bioassays: liver, lung, and kidney. Cancer dose
metrics provided in the model include the area under the concentration curve (AUC) for TCA and
DCA in the plasma, the peak concentration and AUC for chloral in the tracheobronchial region of the
lung, and the production of a thioacetylating intermediate from dichlorovinylcysteine in the kidney.
Additional dose metrics provided for noncancer risk assessment include the peak concentrations
and AUCs for TCE and TCOH in the blood, as well as the total metabolism of TCE divided by the
body weight. Sensitivity and uncertainty analyses were performed on the model to evaluate its
suitability for use in a pharmacokinetic risk assessment for TCE. Model predictions of TCE, TCA,
DCA, and TCOH concentrations in rodents and humans are in good agreement with a variety of
experimental data, suggesting that the model should provide a useful basis for evaluating cross-
species differences in pharmacokinetics for these chemicals. In the case of the lung and kidney
target tissues, however, only limited data are available for establishing cross-species
pharmacokinetics. As a result, PBPK model calculations of target tissue dose for lung and kidney
should be used with caution. Key words: dichloroacetic acid, dichlorovinylcysteine, metabolism,
model, PBPK, pharmacokinetics, risk assessment, trichloroacetic acid, trichloroethanol,
trichloroethylene. - Environ Health Perspect 108(suppl 2):283-305 (2000).
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Introduction
Physiologically based pharmacokinetic
(PBPK) modeling is widely held to be a useful
methodology for improving the accuracy of
chemical risk assessment (1-6). The goal of
PBPK modeling is to simulate the uptake, dis-
tribution, metabolism, and elimination of a
chemical in an organism, using as realistic a
description ofthe relevant physiology and bio-
chemistry as is necessary and feasible (7-10).
For its use in risk assessment, PBPK modeling
attempts to describe the relationship between
external measures of exposure (e.g., amount
administered or concentration in air) and
internal measures ofbiologically effective dose
(e.g., amount metabolized or concentration of
an active metabolite in the tissue displaying
the toxic response) in both the experimental
animal and the human (11,12).
Simple pharmacokinetic approaches have
occasionally been used by regulatory agencies
in risk assessment; for example, the most
recent U.S. Environmental Protection
Agency (U.S. EPA) cancer risk estimates for
trichloroethylene (TCE) were derived using
estimates of metabolized dose (13,14). The
recent U.S. EPA guidelines for the applica-
tion ofinhalation dosimetry in the derivation
of inhalation reference concentrations (15)
also make use ofpharmacokinetic principles.
However, the only case to date where a regu-
latory agency has used a full PBPK approach
in a published risk assessment was in the
U.S. EPA's latest revision ofits inhalation risk
assessment for methylene chloride (16). The
decision to use the PBPK approach in this
case was made only after a period ofconsider-
able controversy, including a workshop spon-
sored by the NationalAcademy ofSciences at
which the usefulness of PBPK modeling for
chemical risk assessment was discussed. The
scientific consensus following the workshop
was that "relevant PBPK data can be used to
reduce uncertainty in extrapolation and risk
assessment" (1). In 1989, after a detailed
multiagency evaluation ofthe available PBPK
information and a review by the U.S. EPA
Scientific Advisory Board, the U.S. EPA
revised the inhalation unit risk and risk-
specific air concentrations for methylene
chloride in its Integrated Risk Information
System (IRIS) (17) database, citing the
PBPK model ofAndersen et al. (18). The
resulting risk estimates were lower than those
obtained by the default approach by nearly a
factor of 10. Application ofthe PBPK model
for methylene chloride in a cancer risk assess-
ment for occupational exposure has also been
described (19-21), and a modified version of
the model was used by the Occupational
Safety and Health Administration (OSHA) in
their rulemaking for methylene chloride (22).
Risk assessments using PBPK models have
also been proposed for many other chemicals,
including not only TCE (23-26), but also
perchloroethylene (PERC) (24,27,28),
ethylene dichloride (29), vinyl chloride
(26,30-32), dioxane (33,34), chloroform
(35), benzene (36), and ethyl acrylate (37).
However, apart from the case with methylene
chloride described above, there still have been
no risk assessments published by a regulatory
agency in which a PBPK model was used for
estimating target tissue dose. Part ofthe rea-
son for the slow progress of incorporating
PBPK modeling in cancer risk assessment is
the concern ofregulatory agency risk assessors
about uncertainties in its implementation.
The potential impact of uncertainty in phar-
macokinetic risk assessment has been a sub-
ject ofsome controversy (19-21,38-43). The
purpose of the study reported here was to
develop a PBPK model for TCE that
included as complete a description as possible
ofall ofthe metabolites and target tissues that
are relevant to the toxicity and carcinogenic-
ity ofTCE and to evaluate the suitability of
the resulting model to provide dosimetry for
each ofthe target tissues in support ofa com-
prehensive pharmacokinetic risk assessment
forTCE.
For completeness, aspects of both the
cancer and noncancer risk assessment con-
texts pertinent to the development and evalu-
ation ofthe PBPK model are discussed in this
article. However, a companion article in this
same issue provides a detailed description of
the application of the PBPK model in a
noncancer risk assessment for TCE (44).
Therefore, the discussions in this article will
focus primarily on the cancer end points.
ToxicityandCarcinogenicityofTCE
TCE produces noncancer toxicity in a variety
of tissues; principal noncancer end points
include neurological, hepatic, renal,
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immunological, and developmental effects
(45-47). The American Conference of
Government Industrial Hygienists (ACGIH)
threshold limit value (TLV) for TCE is cur-
rently 50 ppm as an 8-hr time-weighted
average (TWA), based on central nervous
system (CNS) effects (headaches, fatigue,
irritability), with a short-term exposure limit
of200 ppm to protect against its anesthetic
effects (48). In 1989, as part ofa major rule-
making that promulgated standards for more
than 200 chemicals, OSHA adopted a per-
missible exposure level (PEL) for TCE of50
ppm as an 8-hr TWA based on the ACGIH
TLV (49). However, since the entire 1989
rulemaking has now been overturned by the
courts, the PEL for TCE has returned to its
previous value ofa 100-ppm 8-hr TWA, also
based on CNS effects.
TCE was widely used in industry for
manyyears because ofits relatively low toxic-
ity, its excellent solvent properties, and its
nonflammability. In recent years, however,
use ofTCE has been greatly reduced due to
concerns regarding its carcinogenicity
(46,47). Nevertheless, the question of the
human carcinogenicity ofTCE remains con-
troversial. Although a large number of
studies have demonstrated tumors in animals
following exposure to TCE, the relevance of
these animal results to the question of the
human carcinogenicity of TCE has fre-
quently been challenged (50-52). The
ACGIH has classified TCE into Group A5,
not suspected as a human carcinogen, based
on a well-conducted, negative epidemiologi-
cal study performed in an aircraft mainte-
nance facility at Hill Air Force Base (Ogden,
UT) (53,54). The International Agency for
Research on Cancer (IARC), on the other
hand, classifies TCE into Group 2A, proba-
bly carcinogenic to humans, based on their
assessment ofsufficient data in animals and
limited data in humans (55). The human
evidence considered significant by IARC was
the consistency of an association ofTCE
exposure with slightly increased incidences of
liver/biliary tract tumors and non-Hodgkins
lymphoma in studies ofthree cohorts in the
United States (53), Sweden (56), and
Finland (57), despite the fact that all three
studies were characterized as negative by the
original investigators because the increases
were notstatistically significant.
Requirements for aPBPKModel to
SupportTCERiskAssessments
Quantitative cancer risk estimates for TCE
are currently based on animal bioassays,
specifically liver and lung tumors in mice. In
1983, the U.S. EPA calculated unit risks for
TCE of4.1 x 106 (pg/m3)-1 for inhalation
and 0.54 x 10- (pg/L)-1 for drinking water
using data on the incidence ofliver tumors
in male B6C3F, mice given TCE in an oil
vehicle by gavage (58,59); the linearized
multistage model (60) was usedwith a calcu-
lation ofabsorbed TCE dose scaled by body
surface area (BSA) to obtain these estimates
(61). In 1985, lower unit risks of 1.3 x 106
(pglm3)-1 for inhalation and 0.32 x 10-6
(jg/L)1' fordrinking water were recalculated
on the basis ofthe same oral bioassays, using
the results of pharmacokinetic studies
(50,62,63) to calculate total metabolized
dose in both animals and humans, rather
than absorbed dose. The BSA adjustment
was still applied to obtain the human equiva-
lent dose (13). In 1987, the U.S. EPA calcu-
lated a new inhalation unit risk of 1.7 x 10-
(ig/m3)-1 based on the incidence of mouse
liver and lung tumors in inhalation bioassays
(64-66), again using a calculation ofmetab-
olized dose and the BSA adjustment (16).
Statistically significant increases in the inci-
dence ofrenal tubular cell adenoma and car-
cinoma have also been observed in male
Fischer 344 (F344) rats exposed to TCE by
gavage (67). Although not yet used in a
quantitative risk assessment for TCE, the
incidences of these kidney tumors in rats
have raised concern, since they represent a
rare tumor that has also been associated with
human occupational exposure to TCE (68).
For each of these three target tissues-
liver, lung, and kidney-there is evidence
that the carcinogenicity of TCE may be
associated with one or more of its metabo-
lites: trichloroacetic acid (TCA) and
dichloroacetic acid (DCA) in the liver
(69,70), chloral (CHL) in the lung (71),
and 1,2-dichlorovinylcysteine (DCVC) in
the kidney (72). Thus, to be useful in a
comprehensive cancer risk assessment for
TCE, a PBPK model should include at least
three target tissues-liver, lung, and kid-
ney-along with a description ofthe kinet-
ics ofthe metabolites imputed to play a role
in the carcinogenic activity.
Several target tissues have also been iden-
tified for the noncancer toxicity ofTCE,
including the liver (73), kidney (65,66),
CNS (74), immune system (75,76), and
developing fetus (77). As in the case ofthe
carcinogenicity of TCE, several of these
noncancer end points appear to be associ-
ated with exposure to the metabolites of
TCE rather than to the parent chemical
itself(73,78). In addition to the metabolites
mentioned above with regard to the carcino-
genicity of TCE, it was felt (43) that a
PBPK model developed to support a non-
cancer risk assessment for TCE should also
include a description of the kinetics of
trichloroethanol (TCOH), a major metabo-
lite ofTCE that has been suggested to be
responsible for the observed neurological
effects ofchloral hydrate (79).
Previous PBPKModelingofTCE
A number of PBPK models have been
developed for TCE. However, most are only
parent chemical models; that is, they provide a
pharmacokinetic description ofTCE itself, but
do not include an explicit description ofthe
pharmacokinetics ofany ofthe metabolites
(23,24,80-86). These models have been used
successfully for predicting TCE concentrations
in the blood and tissues (86), for calculating
therespiratory input from inhalation exposures
(81,82,85), and for investigating the impact of
variations in the physiological or biochemical
parameters on thekinetics ofTCE (80,83,84).
Parent chemical models have also been
employed to calculate total metabolized dose
in support ofa cancer risk assessment forTCE
(23,24). However, these parent chemical
models cannot be used for predicting tissue
exposuretospecificmetabolites.
Models ofboth TCE and its metabolites
have also been developed. In a series ofpubli-
cations, Sato and co-workers have described
the use ofa simple PBPK model to study the
kinetics of TCE and its metabolites in
humans (87), to evaluate the impact of
changes in physiological factors (88) and
environmental factors (89) on the kinetics of
TCE in the human, and to predict the effects
ofinteractions with ethanol consumption on
TCE kinetics (90). However, the structure of
these models would not support the animal-
to-human extrapolation ofpharmacokinetic
dose metrics needed for risk assessment.
Fisher and co-workers developed a PBPK
model for TCE and its principal metabolite,
TCA, in the pregnant (91) and lactating (92)
rat, as well as in the mouse (93). These
rodent models, together with a similar model
ofTCE and TCA in the human (94), served
as the basis for a PBPK-based risk assessment
for TCE liver carcinogenicity (25) based on
either total metabolism or AUC for TCA.
These models provided the first successful
cross-species pharmacokinetic description for
a metabolite ofTCE. The model develop-
ment performed in the current study builds
on the work of Fisher and Allen (25) by
adding limited descriptions ofadditional
metabolites (TCOH, DCA, CHL, DCVC)
and target tissues (lungandkidney).
MetabolismofTCE
The following discussion summarizes the
experimental evidence for the nature ofthe
pharmacokinetics and metabolism ofTCE,
which formed the basis for the decisions that
were made regarding the structure and para-
meterization ofthe PBPK model. TCE is a
volatile, lipophilic chemical that distributes
readily throughout all tissues, including the
brain, but partitions preferentially into fat tis-
sue. In contrast, its major metabolite, TCA, is
a water-soluble chemical that preferentially
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distributes into the plasma and richly
perfused organs and is found only in rela-
tively lower concentrations in the musde and
fat. The properties ofTCOH are somewhat
intermediate between the other two com-
pounds (95). Clearance ofTCE occurs both
by exhalation and by metabolism. A
schematic ofthe metabolic pathways forTCE
is shown in Figure 1. The major oxidative
pathway, which takes place primarily (but not
exclusively) in the liver, is shown to the right
ofthe diagram; the minor glutathione-depen-
dent pathway, which involves several loca-
tions induding the liver and kidney, is shown
to theleft.
Oxidative metabolism. The primary route
ofmetabolism for TCE, shown on the right
side ofthe diagram in Figure 1, is oxidation
via the microsomal mixed-function oxidase
(MFO) system, nowreferred to ascytochrome
P450, or CYP (96-102). A minor pathway
for TCE metabolism involving conjugation
with glutathione (GSH) by glutathione trans-
ferase (GST) has also been observed (103).
This pathway, which is shown on the left side
ofthediagram, will bedescribed in thesection
on conjunctive metabolism.
The principal oxidative metabolite formed
in vitro is CHL (96,97,100), which is subse-
quently reduced to TCOH in the cytosol or
oxidized toTCA in either the cytosol or mito-
chondria (96). CHL is not stable in vivo, and
circulating concentrations are relatively low
compared to its breakdown products, TCA
and TCOH (50). Within a few hours ofthe
administration of50 mglkg chloral hydrate to
achild, the rapid initial dearance ofCHLwas
essentially complete. Subsequent blood con-
centrations parallel the time course for
TCOH but are approximately an order of
magnitude lower, suggesting a continuing
production ofCHLfromTCOH (104).
The principal circulating metabolite of
TCE in the blood is TCA, which accumu-
lates in the body due to protein binding
(105) and slow excretion (106), whereas
TCOH is readily excreted (107,108). TCA
appears to be derived both directly from
CHL and indirectly from TCOH
(107-109). TCE is much more extensively
metabolized in the mouse than in the rat,
whether TCE is administered orally (50) or
byinhalation (91).
Based on both in vitroand in vivostudies,
the metabolism ofTCE has beensuggested to
consist ofoxidation ofTCE to CHL by the
MFO system, followed by either oxidation of
CHL to TCA by an aldehyde oxidase (also
known as chloral dehydrogenase) or reduc-
tion to TCOH by alcohol dehydrogenase
(ADH) with subsequent glucuronidation.
Oxidation ofTCOH to TCA by the MFO
system has also been proposed (110).
Consistent with this proposed metabolic
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description, oral co-administration ofethanol
inhibited the metabolism ofinhaled TCE to
TCOH by more than 50% and the produc-
tion ofTCA was essentially abolished while
ethanol was present (110). A similar study in
rats demonstrated qualitatively similar, but
quantitatively much less remarkable, effects of
ethanol co-administration on the kinetics of
orallyadministered TCE (111).
Inhalation exposures ofhuman volunteers
to TCE concentrations from 27 to 201 ppm
showed no evidence ofmetabolic saturation
or ofa change in the proportion ofTCA to
TCOH (112). Saturation ofTCE metabo-
lism has been observed in mice, rats, and dogs
(66,113). The relative proportion of the
major metabolites does not appear to be a
strong function ofdose. However, repeated
dosing does appear to increase the production
ofTCA at the expense ofTCOH (114), and
the relative production ofCO2 increases with
increasing dose in mice (115).
Human in vivo studies with TCE (116)
have identified the major urinary metabolites
to be TCOH (50% ofthe administered TCE
dose), primarily as the glucuronide, and TCA
(19%). Monochloroacetic acid (MCA) was
also identified as a minor metabolite (4%) in
these studies. Another minor metabolite,
N-(hydroxyacetyl)-aminoethanol, has also
been identified in human (and rodent) urine
following TCE exposure, and TCE-derived
oxalic acid has been detected in the rodent
(117). A study of TCE metabolism in
nonhuman primates (118) found that TCA
was partially excreted as the glucuronide,
particularly at longer times after dosing. The
authors suggest that since the detection of
TCA glucuronide had not been reported
previously, TCA excretion may have been
under-reported in earlier studies (such as the
human study cited above). The glucuronida-
tion ofTCA is supported by the observation
that TCA is excreted in the bile ofrats and
mice (114). Urinary excretion represents the
major route of elimination of the metabo-
lites; fecal excretion, in the form ofTCOH
glucuronide, accounts for less than 5% of
the total (118). The low fecal excretion is
apparently associated to some extent with
enterohepatic recirculation ofTCOH (i.e.,
biliary excretion of the glucuronide, fol-
lowed by hydrolysis and reabsorption of
TCOH), which has also been suggested to
occur in rats (119).
DCA has been identified as a minor
urinary metabolite ofTCE (on the order of
1%) in both rats and mice (114,115,
117,120), whereas MCA appears to be pre-
sent at less than 0.1% (114). A recent in vitro
study with mouse and rat liver tissues con-
cluded that unlike most other chlorinated
compounds, which are metabolized primarily
by the microsomal enzymes ofthe MFO sys-
tem, DCA degradation appears to occur pri-
marily in the cytosol in a process that requires
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000
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GSH (121). Although DCA has not been
detected as aurinary metabolite ofTCE in the
human, its kinetics have been studied
(122-124). The peak concentration and
AUC ofDCA in the plasma after intravenous
administration is linear up to approximately
20 mg/kg, but above 20-30 mg/kgsome indi-
viduals display evidence of saturation of
metabolism (121). The apparent volume of
distribution and half-life for DCA are 0.3 L/kg
(range: 0.09-0.60) and 1.05 hr (range:
0.25-1.87), respectively (124). Significantly,
the clearance in humans appears to be much
more rapid than would be expected from allo-
metric scaling ofanimal data. In acomparative
study (122), the half-lives in rats, dogs, and
humans were 2.1-4.4 hr, 17.1-24.6 hr, and
0.33-0.6 hr, respectively. The extremely high
rate ofmetabolism ofDCAin humans is prob-
ably responsible for the failure ofinvestigators
to detect it as aurinarymetabolite ofTCE.
Studies have shown that DCA is produced
from TCA (67). In addition, DCA is pro-
duced in a roughly linear fashion from PERC
(28,125) at levels consistent with production
from TCA, the principal metabolite
of PERC. An analysis of data on the
dose-response and elimination kinetics of
DCA formed from TCE led to the conclu-
sion that another source of DCA was
required in addition to TCA, but that the
data were inconsistent with the second source
being the initial oxidation step (126).
Instead, the production of DCA from
TCOH was hypothesized. A metabolic study
ofTCA and DCA in rats and mice (67)
found that DCA was more rapidly metabo-
lized than TCA. More than 50% of the
administered TCA from an oral dose was
excreted unchanged in the urine as compared
to only 2% ofadministered DCA. Plasma
concentration-time curves for TCA were
similar in mice and rats, whereas those for
DCA were greater in rats than in mice, both
when DCA was administered and when it
was derived fromTCA.
There is evidence that repeated exposure
to high concentrations ofDCA inhibits its
own metabolism. In studies with human vol-
unteers (124,127), the excretion half-life for
DCA increased 2- to 6-fold following
repeated intravenous doses of DCA on the
order of 10-50 mg/kg. Inhibition was only
slowly reversible, taking from 1 week to
greater than 3 months. In the rat, but not the
mouse, exposure to 2 g/L DCA in drinking
water for 14 days curtailed metabolic produc-
tion of CO2 from DCA by more than an
order ofmagnitude and increased the excre-
tion half-life byroughly4-fold (128).
It has recently been reported that under
some conditions DCA can be artificially
produced from TCA in blood samples as an
artifact ofthe analysis. Ifacidification ofthe
sample is performed rapidly aftercollection of
the sample before the hemoglobin iron has
been oxidized by exposure to air, DCAcan be
generated from TCA present in the sample
(129). This artifact may have compromised
some ofthe data reported on DCA plasma
concentrations following administration of
TCA orTCE (66,67).
Metabolism in the lung. As with most
chemicals, the preponderance ofthe metabolic
dearance ofTCE appears to take place in the
liver. It has been demonstrated, however, in
studies with an isolated, ventilated perfused
lung preparation (130), that the male F344
rat lung also possesses a limited oxidative
metabolic capability for TCE. Although the
affinity (K,, forthe lung metabolism observed
in that study was similar to the affinity
observed in the liver, the capacity (Vmax) of
the lung metabolism was less than 1% ofthe
capacity ofthe liver. These results suggest that
lung metabolism is not an important contrib-
utor to total in vivo metabolism in the rat and
that the rat lung does not possess a significant
first-pass (presystemic) clearance capability for
inhaled TCE. However, these results do not
rule out the possibility that metabolism in the
lung could produce sufficient local exposure
to metabolites to produce toxicity and/or
carcinogenicity.
Conjugative metabolism. A small propor-
tion ofTCE appears to be metabolized by
enzymatic conjugation with GSH, principally
by GST in the liver, followed by further
metabolism in the kidney to the cysteine con-
jugate DCVC (131). The GST metabolic
pathway is shown on the left side ofFigure 1.
Delivery ofDCVC to the kidney may also be
mediated by enterohepatic recirculation, in
which GSH conjugate excreted in the bile is
converted by gut bacteria to the cysteine con-
jugate, which is then reabsorbed (132). The
GSH conjugate has been identified both in
vitro, with rat liver microsomes, and (at
5 nmol/L) in the bile ofrats given 2.2 g/kg
TCE in corn oil (103). The cysteine conju-
gate also has been identified in the urine of
animals dosedwith TCE (72).
The bioactivation ofDCVC to a reactive
and mutagenic thioacylating intermediate is
performed by cysteine conjugate I-lyase in
the kidney (133). Although similar P-lyase
activity has been measured in the kidney and
liver, the two enzymes are distinct (134).
Detoxification and dearance ofDCVC takes
place by urinary excretion ofthe N-acetyl
derivative (103,135). In a study with PERC
(136), itwas determined that the excretion of
the N-acetyl derivative was dose related (a
higher fraction of N-acetyl derivative was
excreted at doses where the oxidative pathway
was saturated) and was significantly greater in
the rat than in the mouse. However, measure-
ments ofacid-labile protein adducts associated
with DCVC suggest that the activation of
DCVC in the kidney may be as much as
12-fold greater in mice than in rats and that
the kidney tissue exposure to DCVC-derived
reactive species from oral dosing with TCE
may be twice as great in the mouse as in the
rat (137,138).
The activity ofP-lyase has been measured
in the liver and kidney ofboth humans and
rats. One research group has reported a spe-
cific activity in human kidney on the order of
2.0-3.6 nmol/min/mg cytosol (139,140),
compared to 6.45-7.6 nmol/min/mg cytosol
in the rat (134). Another research group,
however, has reported a maximum velocity
(Vmax) ofonly 0.8 nmol/min/mg cytosol in
the human, with an affinity (Ki) of 0.29
mM, compared to Vmax = 7.5 nmol/min/mg
cytosol and Km = 1.6 mM in rat kidney
cytosol in the same study (141). Data for
PERC on the relative activity ofliver cytoso-
lic GST and kidney cytosolic cysteine conju-
gate ,B-lyase suggest that the human activity
of both enzymes is roughly 10-fold lower
than that in the rat (136). On the other
hand, the specific activity ofN-acetyltrans-
ferase in kidney cytosol appears to be very
similar across species: 0.41 nmol/min/mg
cytosol in the human, compared to
0.35-0.61 in the rat and 0.94 in the mouse
(142).
The fact that N-acetyl-DCVC has been
identified in the urine ofhumans exposed to
TCE both occupationally (142) and in con-
trolled exposures (143) indicates that expo-
sure ofthe kidneyto DCVCdoes occur in the
human. In the occupational study (142), the
concentrations of N-acetyl-DCVC in the
workers' urine was about one-third ofthat
measured in rats dosed orally with 50 mg/kg
TCE. The ratio ofN-acetyl-DCVC to TCA
in theworkers' urine ranged from 0.03 to 0.3,
while in rats it ranged from 0.025 to 0.045,
and in mice from 0.014 to 0.065. However,
more recent data (143) obtained in controlled
studies with both rats and human subjects
suggest that relative urinaryexcretion ofGST-
pathway metabolites from TCE is actually
somewhatlower inhumans than in rats.
Description ofthe PBPK Model
forTCE
PBPKModelStructure
A diagram ofthe PBPK model developed for
TCE and its metabolites is shown in Figures
2 and 3. The model was written in the
Advanced Continuous Simulation Language
(ACSL, Mitchell and Gauthier, Concord,
MA). The parent chemical portion of the
model (Figure 2) includes individual tissue
compartments for the liver, gut tissue, fat,
and tracheobronchial region ofthe lungs. All
other tissues are lumped into rapidly perfused
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Figure 3. PBPK model forTCE: metabolism submodels for lung (A), kidney(B), and liver(C) targettissues.
Figure 2. PBPK model for TCE: parent chemical model.
Abbreviations not listed in Table 1: CA, concentration in
arterial blood; CF, concentration in the fat; CG, concen-
tration in the gut; Cl, concentration in inhaled air; CL,
concentration in the liver; CR, concentration in the richly
perfused tissues; CS, concentration in the slowly per-
fused tissues; CTB, concentration in the tracheo-
bronchial tissue; CV, concentration in venous blood; CVF,
concentration in the venous blood leaving the fat com-
partment; CVG, concentration in the venous blood leav-
ing the gut compartment; CVL, concentration in the
venous blood leaving the liver; CVR, concentration in the
venous blood leaving the richly perfused tissues; CVS,
concentration in the venous blood leaving the slowly
perfused tissues; CVTB, concentration in the venous
blood leaving the tracheobronchial tissue; CX, concen-
tration in exhaled air; KF, rate of production of DCVC in
the kidney; PDOSE, administered oral dose of TCE; QCL
cardiac output; QF, blood flow to the fat; QG, blood flow
to the gut; QL, blood flow to the liver; QP, alveolar venti-
lation; QR, blood flow to the richly perfused tissues; QS,
blood flow to the slowly perfused tissues; QTB, blood
flow to the liver; VR, volume of richly perfused tissue;
VS, volume of slowly perfused tissue; VTB, volume of
the tracheobronchial tissue.
(kidney, brain, alveolar region oflungs, etc.)
and slowly perfused (muscle, skin, etc.) com-
partments. The model includes both inhala-
tion and oral routes of exposure. Oral gavage
is modeled using a two-compartment descrip-
tion ofthe gastrointestinal tract (144), rather
than the single-compartment description used
by Fisher and Allen (25), in order to better
simulate the time course for the uptake of
TCE from corn oil gavage. Allometric scaling
is used throughout the model (volumes scaled
by body weight, flows and metabolic capaci-
ties scaled by body weight to the three-
quarters power, rate constants scaled by body
weight to the negative one-quarter power) to
simplify intraspecies and interspecies extrapo-
lation. Parent chemical dose metrics provided
in the model include the concentration of
TCE in blood and tissues, as well as theAUC
forTCE in the blood.
Lungsubmodel. The model includes three
target tissue submodels in which metabolism
takes place: lung, kidney, and liver (Figure 3).
Michaelis-Menten kinetics are assumed for all
metabolic processes. The tracheobronchial
region ofthe lungs, which receives its own
arterial blood supply, is described separately to
support the modeling ofin situ metabolism in
this region by the Clara cells. This approach
for describing metabolism in the cells lining
the airways of the lung was felt to be more
biologically accurate than the sequential gas
exchange and lung tissue compartments used
in the methylene chloride model (18).
However, as long as metabolism in the lung is
unimportant for presystemic elimination, as is
the case for TCE and methylene chloride, the
two descriptions should yield similar results.
The dose metrics provided for the lung are the
instantaneous concentration and AUC for
CHL in the tracheobronchial region, which is
assumed to be produced by saturable produc-
tion and clearance ofCHL in Clara cells. No
systemic circulation ofCHL is considered in
the model.
Oxidative metabolism. Apart from the
limited metabolism occurring in the lung, the
model assumes that all oxidative metabolism
takes place in the liver. The dose metric pro-
vided to describe metabolism is the total
amount ofTCE metabolized divided by the
body weight. The model does not actually
calculate the formation and metabolism of
CHL in the liver, but instead assumes that
TCA and TCOH are formed in a fixed yield
from the oxidative metabolism ofTCE. In
the model, TCOH can subsequently be oxi-
dized to TCA, conjugated with glucuronic
acid, or reduced to DCA. DCA can also be
produced from the reduction ofTCA. Biliary
excretion ofTCOH glucuronide and entero-
hepatic recirculation of free TCOH is
described, with only the glucuronide being
excreted in the urine. Dose metrics for use
with the liver target tissue include the con-
centrations and AUC for DCA and TCA in
the plasma, as well as a potency-weighted
sum ofthe AUCs for DCA and TCA, which
will be described in the discussion on dose
metric uncertainty. The concentration and
AUC for TCOH in the blood are also pro-
vided as a noncancer dose metric.
Conjugative metabolism. The model also
includes a linear metabolic pathway represent-
ing conjugation ofTCE by GST. The model
implicitly assumes that all GSH conjugation of
TCE in the liver leads eventually to the appear-
ance of DCVC in the kidney. Clearance of
DCVC by N-acetyltransferase into the urine is
also modeled. The dose metric provided in the
model for the kidney (KTOX) is the total pro-
duction of a thioacetylating intermediate from
DCVC dividedbythevolume ofthe kidney.
PBPKModel Parameters
The parameters for the model are listed in
Table 1, with the parameters for the parent
chemical portion ofthe model listed first, fol-
lowed by the parameters for each of the
metabolites in turn.
Parametersfor theparent chemical. The
physiological parameters, with two exceptions,
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Table 1. Parametervalues used inthe PBPK model forTCE.
Parameter Abbreviation Units Mouse Rat Human
Bodyweight BW
Alveolarventilation QPC
Cardiac output QCC
Fractional bloodflows totissues
All rapidly perfused QRC
Gut QGC
Liver QLC
Tracheobronchial QTBC
All slowly perfused QSC
Fat QFC
Fractional volumes oftissues
All rapidly perfused VRC
Gut VGC
Kidney VKC
liver VLC
Tracheobronchial VTBC
All slowly perfused VSC
Fat VFC
Partition coefficients
Blood/air PB
Fat/blood PF
Gut/blood PG
Liver/blood PL
Rich/blood PR
Slow/blood PS
Tracheobronchial/blood PTB
Oral uptake ofTCE
Stomach to liver KAS
Duodenum to liver KAD
Stomach toduodenum KTSO
Fecal excretion KTD
TCE metabolism
Capacity VMC
Affinity KM
Fraction TCA PO
TCOH oxidationtoTCA
Capacity VMOC
Affinity KMO
TCOH reduction to DCA
Capacity VMRC
Affinity KMR
TCOH glucuronidation
Capacity VMGC
Affinity KMG
Kinetics ofglucuronide
Biliaryexcretion KEHBC
Reabsorption KEHRC
Urinaryexcretion KUGC
TCA reduction to DCA
Capacity VMTC
Affinity KMT
Urinaryexcretion KUTC
DCAreduction/elimination
Capacity VMDC
Affinity KMD
Urinaryexcretion KUDC
DCVC kinetics in kidney
Production KFC
Activation KBLC
Clearance KNATC
Chloral kinetics in lung Clara cells
Production capacity VMTBC
Affinity KMTB
Clearance capacity VMCTBC
Affinity KMCTB
Volumes ofdistribution (fraction ofbodyweight)
TCA VDTCAC
DCA VDDCAC
TCOH VDBWC
Fraction of lung containing Clara cells
kg
L/hra
L/hra
0.035* (0.02-0.035)
30
18
0.594
0.141
0.02
0.005
0.406
0.07
0.165
0.042
0.017
0.057
0.0007
0.638
0.072
14
36
1.8
1.8
1.8
0.75
1.8
/hr
/hr
/hr
/hr
mg/hra
mg/l
mg/hra
mg/L
mg/hra
mg/L
mg/hra
mg/L
/hrb
/hrb
/hrb
mg/hra
mg/L
/hrb
mg/hra
mg/L
/hrb
/hrb
/hrb
/hrb
mg/hra
mg/L
mg/hra
mg/L
0
1* (0.27-1.1)
10
0
39*(39-60.)
0.25
0.035* (0.035-0.1)
1*(0.5-1.5)
0.25
10
100
25
1
0
0.5
0*(0.-0.1)
10
0.035*(0.035-0.1)
100
1,000
0.035
0.015
0.4
0.5
3.
0.25
250
250
0.238
0.2
0.65
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0.35* (0.19-0.35)
24
15
70.
24*(18.)
16.5* (13)
0.594
0.153
0.03
0.021
0.406
0.07
0.699
0.181
0.046
0.025
0.301
0.052
0.106
0.03
0.007
0.034
0.0007
0.718
0.124
0.101
0.017
0.004
0.026
0.0007
0.651
0.214
18.5
27.5
1.3
1.3
1.3
0.5
1.3
9.2
73
6.8
6.8
6.8
2.3
6.8
0
0.6* (0.2-0.6)
10
0
12* (12.-20.)
0.25*(0.25-18.)
0.02* (0.02-0.06)
0.12*(0.08-0.25)
0.25
0.1
10
100*(35.- 5O.)
25.
0
10 10
0
10*(6.-10.)
1.5* (1.5-3.)
0.08
25(15.-25.)
250
0.1
10
5
25
l
0
3
0.
10.
0.023
1730
1000
0.023
0.015
37
19
0*(0.-0.3)
0.5
0.1*(0-0.1)
10
0.05
50
1,000
0.05
0.015
17
1.1
0.3
0.25
250
250
0.25
0.2
0.65
0.0045
1.5
250
250
0.1
0.1
0.65
FCLARA - 0.1 0.1 0.1
*Defaultvalue used forcalculation ofrisk assessmentdose metrics; different values(in parentheses) were used forcomparison with pharmacokinetic studies(seetext). "Scaled by bodyweighttothe314
power. bScaled bybodyweighttothe-1/4power.
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were based on the recommendations ofthe
International Life Sciences Institute Risk
Science Institute Working Group on
Physiological Parameters (145). The excep-
tions were the cardiac output (QCC) in the
mouse, based on the recommendations of
Arms andTravis (146), and the alveolarventi-
lation (QPC) in the human, obtained from
Astrand and Rodahl (147). In the model, the
tissue volumes and blood flows for the gut,
liver, and tracheobronchial region are sub-
tracted from the values shown for all rapidly
perfused tissues to obtain the parameters for
the rapidly perfused tissue compartment
shown in Figure 2; those for the fat are sub-
tracted from the values shown for all slowly
perfused tissues to obtain the parameters for
the slowly perfused tissue compartment. The
kidneyvolume shown in the table is used only
in calculations for thekidneydosesurrogate; as
shown in Figure 2, thekidney is not described
separatelyin theparentchemical model.
The partition coefficients for TCE were
obtained from the work ofFisher and Allen
(25,94) and Fisher et al. (93); the partition
coefficients for the gut and tracheobronchial
tissues were assumed to be the same as those
reported for the richly perfused tissues. The
oral uptake parameters were estimated from
data on the appearance of TCE and its
metabolites in the blood following corn oil
gavage in mice and rats (50). For some para-
meters, identified in Table 1, values chosen
for calculating risk assessment dose metrics
were different from those chosen to repro-
duce pharmacokinetic data. For example,
human dose metrics were calculated using a
value for QPC of24, which corresponds to
the U.S. EPA's standard assumption ofa total
ventilation rate of20 m3/day; the correspond-
ing value for QCC of 16.5 was estimated
from Astrand and Rodahl (147). Similarly,
animals used in pharmacokinetic studies tend
to have lower average body weights than ani-
mals used in cancer bioassays, so body
weights appropriate to each case were used in
the model.
Parametersfor oxidative metabolism.
Initial values for the metabolic parameters for
TCE were obtained from the work ofFisher
andAllen (25,94) and Fisher etal. (93); how-
ever, the metabolic and clearance parameters
forTCA, TCOH, and DCAwere derived pri-
marily on the basis offitting the pharmacoki-
netic data depicted in Figures 4-17. When
possible, parameters were also estimated from
independent studies; for example, data from
rodents and humans dosed with TCA were
used to estimate the volumes ofdistribution
and urinary excretion ofTCA (93,109). Since
the model contains a large number of meta-
bolic and clearance parameters, many of
which arehighlycorrelated, the parameter val-
ues estimated by this process (i.e., the kinetic
parameters for TCA, TCOH, and DCA)
cannot be considered to be unequivocally
identified. However, an additional biological
constraintwas applied duringthe modeling by
demanding that all parameters be essentially
constant across exposure scenarios within a
given species and (to the extent justified by
the experimental data) across species. This
constraint greatly reduces the likelihood that
alternative parameterizations could demon-
strate equivalent success in reproducing the
entire bodyofdata. Another constraint on the
parameterization not obvious from the figures
is that ofthe total TCOH extractable from
the blood, roughly 80% is present as free
TCOH in the human (110), whereas roughly
70-85% is present as glucuronide in the
rodent (113,126). In the figures in this arti-
cle, the model concentrations shown represent
either free TCOH (in rodents) or total (in
humans), corresponding to the experimental
dataprovided.
It is informative to note the departures
from simple allometric expectations that were
required on the basis ofthe experimental data
across species. As with most otherxenobiotics,
the mouse shows a relatively greater and more
variable capacity (VMC) for oxidative metab-
olism ofTCE than the rat and human. Also in
keeping with evidence from other P450 sub-
strates, the affinity for oxidative metabolism of
TCE in the human is roughly an order of
magnitude less (i.e., the value ofKM is larger)
than in the rodents. A striking difference
between humans and rodents, which was
clearly demanded by the experimental data,
was that the oxidation ofTCOH to TCA
appears to be a relatively high-affinity (small
value ofKMO), low-capacity (small value of
VMOC) process in the rodent but low affin-
ity, high capacity in the human. It may be
that this disparity reflects the involvement of
different enzymes (e.g., MFO in the rodent vs
ADH in the human). The result of this
species difference is that although the model
uses a similar.value across species for PO
(based on the initial split ofTCA and TCOH
from CHL), the apparent ratio ofTCA to
TCOH predicted (and observed) over the
entire time frame ofan exposure to TCE is
much higher in the human than in the rodent.
The capacity (VMG) for glucuronidation of
TCOH in the human, on the other hand, is
much lower than in the rodent, as reflected in
the greatly different ratios offree TCOH to
glucuronide in the blood, mentioned above.
The prolonged time courses ofTCOH in the
human provide clear evidence ofbiliary excre-
tion (KEHBC) and enterohepatic recircula-
tion (KEHRC). Evidence for enterohepatic
recirculation was equivocal in the rodents,
however, with recirculation being required to
reproduce some data, but being contradicted
byotherdata in the samespecies.
The leastwell-characterized portion ofthe
oxidative metabolism pathway is the descrip-
tion ofthe kinetics ofDCA. The only species
in which DCA has been reproducibly
detected in the blood following TCE expo-
sure is the mouse, and these datawere used to
obtain values for the production (VMRC and
KMR) and clearance (VMDC and KMDC)
in the mouse. (The artifactual production of
DCAfrom TCA in blood samples, noted ear-
lier in this report, may have compromised
some ofthe data on DCA plasma concentra-
tions used to parameterize the production
and clearance of DCA in the mouse.)
Assuming that the affinities (KMR and
KMD) are constant across species, the capaci-
ties in the other species were estimated (for
VMDC) from the reported half-lives ofDCA
across species (122), or (for VMRC in the
human) from data on peak DCA concentra-
tions in human subjects exposed to TCE by
inhalation (148). Since the clearance ofDCA
in the rat is actually slower than in the mouse
(70), the capacity for production of DCA
(VMRC) in the rat was set to the lower
human value rather than that ofthe mouse to
be consistent with the failure ofinvestigators
to observe DCA in the plasma ofthe rat fol-
lowing administration ofTCE (69). The
renal clearance of DCA (KUDC) was
assumed to be the same as that observed for
TCA (KUTC) in the same species. As men-
tioned earlier, the most striking departure
from allometric expectations for the kinetics
ofDCA is the extremely high clearance in the
human compared to the otherspecies.
Parametersfor lung metabolism. The
parameters in the PBPK model for predicting
the lung dose metric are the capacity and
affinity for the production ofCHL (VMTBC
and KMTB) and the capacity and affinity for
its clearance (VMCTBC and KMCTB). In
the model, the production ofCHL in the tra-
cheobronchial region was assumed to be asso-
ciated with the P450 activity in that tissue.
This is the assumption that was made in the
pharmacokinetic risk assessment for methyl-
ene chloride (18). The approach used in that
risk assessment was also used to obtain the
parameters in this case: the affinity in the lung
was assumed to be the same as in the liver for
the same species, and the relative capacity of
the lung compared to the liver was deter-
mined on the basis ofP450 activity measured
with standard substrates (18). Based on these
data, P450 activity falls offmuch more rapidly
with body weight than would be expected
from allometric considerations. No data were
available on the clearance ofCHL in the lung
across species; therefore, it was assumed to be
a low-affinity, high-capacity enzyme system
such as ADH. The parameters in the PBPK
model were chosen such that concentrations
ofCHL in the lungofthe mousepredicted by
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the modelwere consistent with those observed
in recent studies (149). Itwas further assumed
that the clearance ofCHL in the lung scales
across species according to allometric expecta-
tions (i.e., by body weight to the 3/4 power).
This assumption leads to much lower CHL
concentrations in the lungs of rats and
humans compared to mice for the same TCE
exposure conditions. An alternative assump-
tion would have been that the activity ofthe
enzyme responsible for the clearance ofCHL
scales in the same way as P450. This assump-
tion would lead to similar concentrations of
CHL in the lungs ofmice, rats, and humans
for the same TCEexposure conditions.
Parametersfor conjugative metabolism.
The parameters in the PBPK model for pre-
dicting the kidney dose metric are the pro-
duction of DCVC by the GST pathway
(KFC), its activation by 3-lyase (KBLC), and
its clearance by N-acetyltransferase
(KNATC). First-order rate constants are
used because the production ofmetabolites
by the GST pathway is quite low, and satura-
tion ofenzyme capacity is unlikely. As dis-
cussed earlier, the capacity and affinity of
i-lyase in the kidney have been measured in
both rats and humans (141). These data
were used to estimate the apparent first-order
rate constants (KBLC) used in the model.
No data were available on the activity of
I-lyase in the mouse, so the relationships
between P-lyase metabolic parameters in
mice and rats reported for trichlorovinyl-
cysteine derived from PERC (136) were
assumed to apply-for DCVC as well. For
N-acetyltransferase, onlyspecific activity data
across species are available (142). These data
were converted to the corresponding rate
constants (KNATC) by assuming the affinity
ofN-acetyltransferase for DCVC is the same
as that measured for ,B-lyase in the same
species. This assumption is supported by the
similarity ofthe affinities of N-acetyltrans-
ferase and I-lyase for DCVC in the rat: 3.3
mM and 1.6 mM, respectively (141,150).
Finally, measurements ofoxidative and
conjugative metabolites in the urine following
TCE exposure (143) were used to obtain
estimates ofthe GST pathway rate constant
(KFC). The oxidative pathway was repre-
sented by total excretion of TCA plus
TCOH, while the conjugative pathway was
represented by excretion of 1,2-DCVC. Data
from the same study on excretion of
2,2-DCVC were not used. Unlike 1,2-
DCVC, there was no evidence of a dose
response for 2,2-DCVC as a function ofTCE
exposure in humans or rodents; similar
amounts of 2,2-DCVC were excreted for
TCE exposures ranging from 40 to 160 ppm.
Ignoring 2,2-DCVC is unlikely to signifi-
cantly affect the risk assessment for TCE,
since 1,2-DCVC is clearly the more toxic and
mutagenic ofthe two isomers (151).
The results ofthis analysis are shown in
Table 2. In performing this analysis, all ofthe
parameters in the model were set at the
default values except VMC, KM, and KFC
(in particular, KBLC and KNATC were set
to the values calculated as described above).
The values ofVMC, KM, and KFC in the
model were then varied to bring the model
into agreement with the data for both the
oxidative (MFO) and conjugative (GST)
pathways. It can be seen that the model could
be made to agree quite well with the urinary
data when allometric scaling was assumed for
conjugative metabolism (i.e., using the same
value ofthe scaled parameter KFC in rat and
human). Although it was necessary to adjust
KM to obtain the best agreement with the
MFO pathway data, allometric scaling of
conjugative metabolism also gave the best
agreement with the GST pathway data when
the default values for KM were used. This
result is consistent with the observed allo-
metric scaling of the GST pathway for
methylene chloride (152).
Additional data on urinary metabolite con-
centrations following oral gavage ofrats with
50 mg/kg TCE (142), although not suitable
for comparing with the model, were consistent
with the inhalation data, suggesting that there
is not an effect due to route ofexposure.
Therefore, the value estimated from inhalation
was used to obtain the kidney dose metrics for
the ratforboth inhalation and oralexposures.
Table 2. Estimation ofglutathione pathwayactivityfrom urinary excretion data.
MFO pathwaya GSTpathwayb Model
Total urinary excretion (pmol TCA +TCOH) (pg NA-1,2-DCVC) parameters
of metabolites Measured Predicted Measured Predicted VMC/KM/KFC
Rat, 6-hr inhalation
40 ppm 6.9 8.9 0.001 0.001 12/18/0.015
80 ppm 13.0 16.9 0.002 0.002 12/18/0.015
160 ppm 33.3 30.6 0.006 0.005 12/18/0.015
Human, 6-hr inhalation
40 ppm 823 943 0.074 0.074 10/3/0.015
80 ppm 1,775 1,762 0.161 0.160 10/3/0.015
160 ppm 3,080 3,029 0.223 0.379 10/3/0.015
Metabolites collected for 48 hr after exposure [(1431, Tables 1 and 21; reported as total pmoles TCA + TCOH excreted. bMetabolites
collected for48 hrafter exposure[(143), Figures 5 and71; reported as total micrograms N-acetyl-1,2-DCVC excreted.
PBPKModelValidation
In the strictest sense ofthe word, validation
of a PBPK model would require testing the
predictions of the model against data not
used in the development and parameteriza-
tion ofthe model (153). Ideally, each ofthe
model parameters would have been esti-
mated from separate experiments and the
performance of the model could then be
tested against pharmacokinetic data such as
shown in Figures 4-17. In practice, there are
simply not enough experimental data to sep-
arately identify all of the parameters in a
model as complex as the PBPK model for
TCE described in this article. Moreover, as
in this case, there are often no data available
with which to validate important compo-
nents of the model. Therefore, the validity
of the model for its intended purpose must
be evaluated on the basis ofthe comprehen-
siveness of its predictive power and the rea-
sonableness ofthe parameters used to fit the
various data sets. The parameterization of
the PBPK model for TCE has already been
discussed. The ability ofthe model described
to reproduce data on TCE and TCA kinet-
ics in the mouse, rat, and human for both
inhalation exposure and oral gavage is
shown in Figures 4-17. In addition, these
figures demonstrate the successful expansion
ofthe Fisher and Allen model ofTCE and
TCA to describe TCOH kinetics in mice,
rats, and humans, as well as DCA in the
mouse. No data suitable for plotting were
available for validation ofthe model predic-
tions for CHL in the lung, DCVC in the
kidney, or DCA in the human.
Figures 4-7 demonstrate the ability ofthe
PBPK model to simulate the kinetics ofTCE
and its metabolites in mice. Figure 4 compares
thepredictions ofthe modelwith experimental
data on the concentrations ofTCE in the
blood and TCA in the plasma ofmale and
female B6C3F1 mice exposed to 110 and 368
ppm, respectively, ofTCE by inhalation for
4 hr (93). The model overpredicts the blood
concentrations ofTCE duringthe exposure by
about 50%, but provides agood description of
the time course forTCA in the plasma. Figure
5 shows the ability ofthe model to simultane-
ously reproduce experimental data on the
blood concentrations ofTCE, TCA, and
TCOH in mice exposed to 1,000 mg/kgTCE
bycorn oil gavage (50). The model is also able
to simulate (Figure 6) the time course ofTCE,
TCA, TCOH, and DCA in the B6C3F,
mouse following an oral dose of499 mg/kg in
an aqueous vehicle (126). The DCA data at 6
and 9 hr in Figure 6 are suspect due to prob-
lems with the analytical method (129). Figure
7 shows the predictions ofthe model for DCA
data collected under the same experimental
conditions but for oral administration of99
and 1,791 mg/kgTCE.
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 290PBPK MODEL OFTCE AND ITS METABOUTES
10 15
Time (hours)
A m!
E
20 25 c
0
0
* TCE 0
A TI%A 0
0 5 10 15 20 25 30 35
Tirne (hours)
Figure 4. Comparison of predicted and experimental concentrations of TCE in blood
and TCA in plasma in B6C3F, mice exposed to TCE by inhalation. The figures show
TCE-blood and TCA-plasma concentrations in (A) male mice exposed for 4 hr to 110
ppm TCE vapors, and (B) female mice exposed for 4 hr to 368 ppm TCE vapors. Kinetic
data are taken from Fisher et al. (93).
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Figure 6. Mean observed and predicted blood concentrations ofTCE (A) and metabolites TCA(B), TCOH (C), and DCA
(D)following an oral dose of499 mg/kg TCE in B6C3F1 mice. Kinetic data are taken from Templin et al. (126).
Figures 8-13 show the results ofexercising
the model against similar data in the rat.
Figure 8 compares the predictions of the
model with experimental data on the concen-
trations ofTCE in the blood and TCA in the
plasma ofmale and female F344 rats exposed
to TCE by inhalation for 4 hr (93). The
model overpredicts the blood concentrations
ofTCE in the female rats during the exposure
byabout 50%, butprovides agood description
6
( Time (hours)
Figure 7. Mean observed and predicted plasma concen-
trations of DCA following oral doses of 99 or 1,971
mg/kg TCE in B6C3F1 mice. Kinetic data are taken from
Templin et al. (126).
ofthe time course for TCA in the plasma of
the female rats, and forboth TCEandTCAin
the male rats. Figure 9 shows the ability ofthe
model to simultaneously reproduce experi-
mental data on the blood concentrations of
TCE, TCA, and TCOH in rats exposed to
1,000 mg/kg TCE by corn oil gavage (49). As
shown in Figures 10-13, the model is also able
to simuiate the time courses ofTCE, TCA,
and TCOH in the F344 rat following oral
doses of100, 197, 591, and 3,000 mg/kg in an
aqueousvehicle (69,113).
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Figure 8. Comparison of predicted and experimental
concentrations of TCE in blood and TCA in plasma in
F344 rats exposed to TCE by inhalation. The figures
show(A)TCE blood concentrations in male rats exposed
for4 hrto 529 ppm TCE vapors and TCA plasma concen-
trations in male rats exposed for 4 hr to 505 ppm TCE
vapors; (B) TCE blood and TCA plasma concentrations in
female rats exposed for 4 hr to 600 ppm TCE vapors.
Kinetic data are takenfrom Fisher etal. (93).
Finally, Figures 14-17 demonstrate the
ability ofthe model to describe the human
kinetics ofTCE and its metabolites, TCA
and TCOH. Figure 14 compares the model
predictions with experimental data collected
on two different occasions for TCE in the
blood, as well as for TCA and TCOH in the
plasma and urine, following a 6-hr exposure
of human subjects to 100 ppm TCE
(109,110). The model provides a reasonable
simulation ofthe time course ofTCE in the
blood during the exposure and for several
hours afterward but underpredicts the long-
term concentration ofTCE in the blood.
Model predictions for TCA in plasma and
urine are close to the experimental data
throughout the experiment. The model over-
predicts the early concentrations ofTCOH in
the plasma while underpredicting the later
concentrations; however, the model predic-
tions ofTCOH glucuronide in the urine are
very close to the data throughout the experi-
mental period. Figure 15 demonstrates the
ability of the model to reproduce data on
multiple exposures (in this case, 4-hr expo-
sures ofhuman subjects to 70 ppm TCE
repeated daily for 5 days) (154). The model
underpredicts the peak concentration ofTCE
in the blood in this experiment by a factor of
2 but does reproduce the progressive failure
ofTCE concentrations to return to zero at
the end ofthe day after repeated exposure.
The model also provides a reasonable simula-
tion of the accumulation and excretion of
TCA in the plasma and urine, as well as
TCOH glucuronide in the urine. Figures 16
and 17 show similar results for TCE in
exhaled air as well as TCA and TCOH in the
urine ofhuman subjects exposed 7 hr perday
for 5 days to 200 ppm TCE (155), and for
TCA and TCOH in the plasma and urine of
human subjects exposed 5 days for 6 hr to
50 ppmTCE (110).
It can be readily seen from Figures 4-17
that it was not possible to obtain complete
agreement between the model and each ofthe
studies investigated using a single set ofpara-
meters in each species. This failure undoubt-
edly results from a combination ofvariation
across individuals and animal strains, experi-
mental error, and model error. Nevertheless,
given the general agreement of the model
with a variety ofdata on TCE, TCA, and
TCOH concentration time courses in both
rodents and humans, there can be relatively
high confidence in dose metrics based on the
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Figure 9. Mean observed and predicted blood concentrations ofTCE (A), TCA (B), and
free TCOH (C)following corn oil gavage with 1,000 mg/kg TCE in rats. Kinetic data are
taken from Prout etal. (50).
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Figure 10. Mean observed and predicted blood concentrations of TCE (A), TCA (B),
and free TCOH (C) following an oral dose of 100 mg/kg TCE in F344 rats. Kinetic data
aretaken from Templin et al. (113).
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predictions of the PBPK model for these
chemicals. Similarly, model predictions for
the total amount ofTCE metabolized per
kilogram bodyweight were generally within a
factor of 2 of data on inhalation and oral
exposures ofmice, rats, and humans (50,62,
63,114,117). Unfortunately, as mentioned
earlier, there is a lack ofsimilar data to pro-
vide confidence in the model predictions for
DCVC in the kidney, CHL in the lung, and
DCAin the human.
Sensitivity and Uncertainty
Analysis
In order to evaluate the level ofconfidence
that could be given to the calculations per-
formed with the PBPK model, a series of
quantitative and qualitative analyses were per-
formed to characterize the uncertainty in the
model structure, parameterization, and dose
metric selection. Since the intended use ofthe
PBPK model is to calculate target tissue dose
metrics, any evaluation ofthe model should
focus on this aspect ofthe model capabilities.
Therefore, both the sensitivity analysis and
the uncertainty analysis were conducted with
respect to model predictions of the target
2 4 6 8
Time (hours)
tissue dose metrics. These dose metrics are
calculated as a lifetime average daily dose
(LADD). The most obvious (and most time-
consuming) way to calculate a LADD with
the PBPK model is to run the model for the
entire lifetime ofthe animal orhuman, repro-
ducing the entire exposure scenario. For
example, the dose metrics for the inhalation
bioassay performed by Maltoni et al. (65,66)
could be obtained by simulating repeated
exposures at each concentration for 7 hr per
day, 5 days per week, until 78 weeks, at
which point the exposures would be termi-
nated and the simulation continued until 104
weeks. Dividing the resulting dose metrics by
728 days would produce the LADDs. In
practice it is faster and sufficiently accurate to
run the exposure scenario only until the
weekly increase in the dose metric is constant,
multiply the weekly result by the fraction of
lifetime over which the exposures were con-
ducted, and divide by7 to obtain the LADD.
Except for the AUC for TCA in the human,
which can sometimes take more than 7 weeks
to reach steadystate, simulations usually need
to be run foronly2 or 3 weeks to obtain dose
metrics in this fashion.
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Figure 13. Mean observed and predicted blood concen-
trations ofTCE(A), TCA(B), and free TCOH (C)following
an oral dose of 3,000 mg/kg TCE in F344 rats. Kinetic
data aretaken from Larson and Bull (69).
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Figure 11. Mean observed and predicted blood concentrations of TCE (A), TCA (B),
and free TCOH (C) following an oral dose of 197 mg/kg TCE in F344 rats. Kinetic data
are taken from Larson and Bull (69).
Figure 12. Mean observed and predicted blood concentrations of TCE (A), TCA (B),
and free TCOH (C) following an oral dose of 591 mg/kg TCE in F344 rats. Kinetic data
are taken from Larson and Bull (69).
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table are defined in Table 1. Sensitivity coeffi-
cients ofless than 0.1 in absolute value were
omitted from the table for clarity, and
coefficients above 0.5 areoudined.
It can be seen that ofthe 29 parameters in
the TCE/TCA portion ofthe model, 12 have
essentially no impact on risk predictions
based on the two dose metrics, and only 5
have a significant impact: the alveolar ventila-
tion (QPC), the capacity for metabolism of
TCE (VM), the fraction ofTCA produced
from the metabolism ofTCE (PO), the
volume ofdistribution (VDTCAC) and rate
ofexcretion (KUTC) ofTCA. None of the
Figure 14. Mean observed and predicted kinetics of TCE
and its metabolites during and after a single 6-hr expo-
sure of human subjects to 100 ppm TCE. Kinetic data are
taken from Muller et al. (109) and Muller et al. (110): (A)
TCE blood concentrations (mg/L); (B)TCAplasma concen-
trations (mg/L); (C) cumulative urinary TCA excretion
(mg); (D) total TCOH plasma concentrations (mg/L); (E)
cumulative urinaryTCOH excretion (mg).
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Figure 15. Mean observed and predicted kinetics of TCE and its metabolites during and after 4-hr exposures of
human subjects to 70 ppm TCE for 5 days. Kinetic data are taken from Monster et al. (154): (A) TCE venous blood
concentrations (mg/L); (B) TCA plasma concentrations (mg/L); (C) cumulative urinary TCA excretion (mg); (D) cumula-
tive urinaryTCOH excretion (mg).
parameters are associated with sensitivities
greater than 1.0, indicating that there is no
amplification oferror from the inputs ofthe
model to the outputs. This is, ofcourse, a
desirable trait in a model to be used for risk
assessment.
Sensitivities for the other metabolites in
the model are not shown, but the results were
similar to those for TCA; that is, none ofthe
parameters were associated with sensitivities
greater than 1 in absolute value, and (except
for QPC) only the parameters directly related
to the production and dearance ofa metabo-
lite were associated with significant sensi-
tivities (close to 1) for dose metrics based on
that metabolite.
PBPKModel ParameterUncertainty
There are a number ofways ofcharacterizing
the uncertainty associated with use ofa PBPK
model. Thebestapproach depends on thelevel
ofuncertainty. In the case ofthe TCE model,
the level ofuncertainty varies considerably
from one portion ofthe model to another.
Some parameters in the model, such as those
forTCE, TCA, andTCOH, are relativelywell
established by data, and the uncertainties can
be addressed fairly quantitatively. Under these
conditions the preferred method for character-
izing the overall model uncertainty is to per-
form MonteCarlo analysis, as discussedbelow.
On the other hand, other parameters in the
model, such as those associated with the pro-
duction and clearance ofDCVC in the kidney
and CHL in the lung, are based on inadequate
E A
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Figure 16. Mean observed and predicted kinetics ofTCE
and its metabolites during and following interrupted,
7-hr exposures of human subjects to 200 ppm TCE (3-hr
exposure, a half-hour break, then 4-hr exposure) for 5
days. Kinetic data are taken from Stewart et al. (155):
(A) TCE concentration in exhaled breath (ppm); (B)
cumulative urinary TCA excretion (mg); (C) cumulative
urinaryTCOH excretion (mg).
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PBPKModelParameterSensitivity
Table 3 shows the normalized analytical
sensitivities for the TCE and TCA parameters
in the PBPKmodel described above. The nor-
malized analytical sensitivity coefficient repre-
sents the fractional change in output
associated with a fractional change in the
input parameter. For example, ifa 1% change
in the input parameter results in a 2% change
in the output, the sensitivity coefficient would
be 2.0. In Table 3, the outputs evaluated are
the dose metrics for the total amount ofTCE
metabolized per kilogram body weight and
the AUC for TCA. The parameters in the
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and often conflicting data, and the uncertain-
ties cannot be adequately quantified to support
such a rigorous analysis. For these aspects of
the model, an appropriate method for charac-
terizing uncertainty is to simply calculate the
range ofdose metrics that could reasonably be
expected given the existingdata.
Liver dose metric: Monte Carlo analysis.
The sensitivity analysis described above does
not consider the potential interactions
between parameters; the parameters are
tested individually. Also, sensitivity analysis
does not reflect the uncertainty associated
with each parameter. For example, the fact
that the output is highly sensitive to a partic-
ular parameter is not important ifthe para-
meter is known exactly. To estimate the
combined impact of uncertainty regarding
the values ofthe various parameters, a Monte
Carlo analysis was performed on an early ver-
sion of the PBPK model for a characteristic
dose metric, the average daily AUC for TCA
in the plasma. The version of the model
tested in this analysis was essentially identical
to that ofFisher and Allen (25) and did not
include the description ofTCOH and DCA
kinetics provided in the current version of
the model. In support of the Monte Carlo
analysis, the distributions ofpossible values
for each of the input parameters were esti-
mated, as shown in Table 4. The Monte
Carlo software (PBPK_SIM, K.S. Crump
Group, Ruston, LA) randomly selects a set of
parameter values from the distributions for
the bioassay animal and runs the PBPK
model to obtain dose metric values for each
ofthe bioassay dose groups. It then selects a
set of parameter values from the distributions
for the human and runs the PBPK model to
obtain a dose metric value for a specified
human exposure scenario. This process is
repeated the specified number of times (400
in this case) until the distributions of dose
metrics have been obtained.
Table 4 lists the means and coefficients of
variation (CV) used in a Monte Carlo uncer-
tainty analysis ofthe AUC-TCA dose metric.
Truncated (greater than zero) normal distribu-
tions were used for all parameters except the
kinetic parameters, which were assumed to be
log-normally distributed. The CVs for the
physiological parameters were estimated from
data on the variability ofpublished values
(146,156). In order to maintain mass balance
in the PBPK model, after sampled parameter
values for cardiac output and fractional tissue
blood flows were used to calculate blood
flows to each ofthe tissues, total cardiac out-
put was recalculated as the sum of the indi-
vidual tissue blood flows. The CVs for the
partition coefficients were based on repeated
determinations for two other chemicals,
PERC (28) and chloropentafluorobenzene
(6). The CVs for the metabolic and kinetic
constants were estimated from a comparison
of reported values in the literature and by
exercising the model against various data sets
to determine the identifiability of the para-
meters estimated from pharmacokinetic data.
It should be understood, however, that the
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most uncertain part ofuncertainty analysis is
quantifying uncertainty.
The results ofthe Monte Carlo analysis
are shown in Table 5, which lists the means
and 5th and 95th percentiles for the animal
and human dose metrics. For dose metrics
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Figure 17. Mean observed and predicted kinetics of TCE and its metabolites during and after 6-hr exposures of
human subjects to 50 ppm TCE for 5 days. Kinetic data are taken from Muller et al. (110): (A)TCA plasma concentra-
tions (mg/L); (B) cumulative urinary TCA excretion (mg); (C) total TCOH plasma concentrations (mg/L); (D) cumulative
urinaryTCOH excretion (mg).
Table 3. Normalized analytical sensitivity coefficients for PBPK model predictions of amount TCE metabolized per kg
bodyweight(AMET) and area underthe curvefortrichloroacetic acid (AUC-TCA).a
Parameter
BW
QCC
QPC
QFC
QGC
QLC
QRC
QSC
QTBC
VFC
VGC
VKC
VLC
VRC
vsc
VTBC
VDTCAC
PB
PF
PG
PL
PR
PS
PTB
KAS
VMC
KM
PO
KUTC
Mouse gavage Mouse inhalation Human inhalation Human ingestion
(1,000 mg/kg) (1,000 ppm) (1 ppm) (1 mg/kg/day)
AMET AUC-TCA AMET AUC-TCA AMET AUC-TCA AMET AUC-TCA
-0.1
-0.3
0.3
0.3
0.3
-0.4
0.6
1.1
-0.3
0.3
0.3
0.3
-0.4
0.7
1.0
-1.0
-0.2
0.1
0.1
0.1
0.3
0.1
0.7
"Units: AMET (mg/kg bodyweight); AUC-TCA (mg-hr/L).
1.0
0.1
0.1
0.1
0.3
0.1
0.7
1.0
-0.9
-0.3
0.3
0.7
-0.1
0.3
0.1
0.3
0.1
-0.2
-0.2
0.3
0.7
-0.1
0.3
0.1
-0.1
-0.9
0.3
-0.1
0.2
-0.2
1.0
-0.1
-0.1
-0.1
0.1
0.2
-0.2
0.1
-0.1
-0.1
-0.9
0.1
0.2
-0.2
1.0
-0.1
-, Less than 0.1 in absolute value.
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Table 4. Parameter values and coefficients of variation
(CV) for Monte Carlo analysis of the TCE/TCA portion of
the PBPKmodel.a
Preferred value CV(%)C
Parameterb Mouse (M/F) Human Mouse Human
BW 0.031/0.027 70.0 11.0
QPC 29.0 24.0 58.0
QCC 16.5 16.5 8.5
Tissue blood flows(fraction ofcardiacoutput)
QGC 0.165 0.195 25.0
QlC 0.035 0.07 96.0
QFC 0.03 0.05 60.0
QSC 0.25 0.24 40.0
QRC 0.47 0.395 50.0
QTBC 0.05 0.05 50.0
Tissue volumes (fraction ofbodyweight)
VGC 0.031 0.045 30.0
VLC 0.046 0.023 6.0
VFC 0.04/0.1 0.16 30.0
VSC 0.553/0.513 0.48 30.0
VRC 0.049 0.039 30.0
VTBC 0.0007 0.0007 30.0
Partition coefficients
PB 13.2/14.3
PG 2.0/1.6
Pl 2.0/1.6
PF 41.3/31.4
PS 1.0/0.5
PR 2.0/1.6
PTB 2.0/1.6
9.2
6.8
6.8
73.0
2.3
6.8
6.8
Kinetic parameters
VMC 39.0/27.6 12.0
KM 0.25 1.5
VDTCAC 0.238/0.176 0.1
KAS 1.2/1.0 -
P0 0.06/ 0.33
0.07-0.18d
KUTC 0.035/0.125 0.023
'Based on an earlier version ofthe model befc
TCOH and DCA were added. bDefinitions of p,
same as those given in Table 1. cCoefficient
100 x standard deviation/mean. dDose-depe
used in this earlierversion ofmodel.
based on the average daily AUC
the plasma, the 5th and 95th po
the dose metric distributions a
within a factor of2 to 3 ofthe n
ofthe 90% confidence intervals
metrics range over somewhat ]
order ofmagnitude. These result
to those reported for a PBPK mo
ylene chloride (21) and are probal
tative ofthe uncertainty associate
dose metrics in the validated poi
model such asAUC-TCOH, AU
the mouse), and total metabolism
Lung dose metric. The great4
uncertainty regarding the calcul
lung dose metric is the lack of
metabolic clearance of CHL i
Table 6 shows the predicted lung
for the principal inhalation bioas
ing a dose response for lung tum4
for the highest oral exposure ofth
the highest rat exposures, and
human exposure scenarios. TI
exposures have been ordered accc
30.0
15.8
9.1
10.0
35.0
30.0
15.0
20.0
20.0
10.0
5.0
30.0
30.0
10.0
10.0
Table 5. Estimated variationa in mouse and human dose metrics for area under the curve for trichloroacetic acid
(mg-hr/L).
Mouse inhalationb
Mean
5th percentile
95th percentile
Mouse gavagec
Mean
5th percentile
95th percentile
Human inhalation
Mean
5th percentile
95th percentile
Human drinking water
Mean
5th percentile
95th percentile
i100 pm
495
148
1,133
1.169mg/kg
1,197
384
2,576
1 ppb
0.293
0.087
0.630
0.012
0.003
0.026
30p.pDm
532
167
1,179
2.339 mg/kg
1,519
481
3,381
00ppRm
811
271
2,033
'Based on 400-iteration Monte Carlo analysis. bConcentrations used in inhalation bioassay 165,66). 0Doses employed in oral
bioassay(59).
predicted value ofthe LADD based on the
A T Tr' C-. CrTT T- *Lr- -- ^C to ^^Ann
15.0 10.0 nut- or I[ rL. ill neI casC or neI rat anaU
30.0 3010 human, two dose metric values are shown.
20.0 20.0 The first number represents the dose metric
30.0 30.0 calculated based on the assumption that the
20.0 20.0 dearance ofCHL scales across species accord-
30.0 3010 ing toallometricexpectations(proportional to
bodyweight to the3/4power).
20.0 30.0 The much lower dose metric values in the
30.0 500 human compared to the rodent resultprimar-
30.0 3010 ily from theassumption that the clearance of
50.0 - CHL in thelungscales according to allometric
30.0 30.0 expectations, whereas measured P450 activity
in the lung across species is used directly. The
30.0 30.0 measured lung P450 activity falls offmuch
oredescriptions of more rapidlythan allometric expectations, per-
oarameters are the haps due to themuch greaternumberofmeta-
indentvalues (25) bolicallyactive Claracells in the mouse than in
the human (71). Although no data could be
found on the cross-species activity ofADH in
for TCA in the lung, ADH activity in the rat airway
ercentiles of appears to be restricted to the Clara cell (157),
Ire generally suggesting that the enzymes responsible for the
nean, and all clearance of CHL may also fall off more
for the dose rapidlythan allometricexpectations.
less than an The alternative dose metric calculations,
ts are similar shown in parentheses in Table 6, were
del ofmeth- obtained under the assumption that the dear-
blyrepresen- ance ofCHL scales in the same way as lung
d with other P450. Using this assumption yields dose met-
rtions ofthe rics roughly 10-fold higher in the rat and
JC-DCA (in 700-fold higher in the human. This signifi-
ofTCE. cant uncertainty regarding the relative expo-
est source of sure to CHL across species could be resolved
lation ofthe by the collection ofdata on CHL dearance in
data on the the lung across species, similar to the data
in the lung. that have been reported on P450. Ofcourse,
dose metrics as discussed in the section on the lung para-
ssays provid- meters, there are also other sources ofpara-
ors (64-66), meter uncertainty associated with the lung
be mouse, for dose metric. Additional experimental data are
for several needed before a quantitative estimate ofthe
he different overall uncertainty associated with this metric
)rding to the could be confidentlyattempted.
Kidneydose metric. The overriding source
ofuncertainty regarding calculation ofthe
kidneydose metricis the inadequateandoften
conflicting data in the literature for the con-
jugative pathway. Specific data gaps include
the affinity ofkidney N-acetyltransferase for
DCVC in the human and the activities ofthe
GST pathway in the rat and human. Table 7
shows the predicted kidney dose metrics for
the principal bioassays providing a dose
response for kidney tumors (65-67), for the
highest oral exposure ofthe mouse, and for
several human exposure scenarios. The differ-
ent exposures have been ordered according to
the predictedvalueofthe LADD based on the
production ofthe toxic thiol per gram ofkid-
ney tissue (KTOX). The human dose metrics
shown in Table 7 are those calculated assum-
ing allometric scaling ofthe GSH pathway
rate constant. There is, ofcourse, additional
parameter uncertainty associated with the
limited data on the other enzymes involved
in the production, intoxication, and clear-
ance ofDCVC. As with the lung target tis-
sue, it will not be possible to provide an
accurate assessment ofthe overall uncertainty
in the kidney dose metric until reproducible
data are collected.
DoseMetricSdectionUncertainty
The pharmacokinetic dose metrics most
commonly applied to characterize the expo-
sure of a tissue to a chemical are the peak
concentration and the AUC, and these are
the principal types ofdose metrics provided
in the PBPK model. However, there are
other possible forms for dose metrics that
might be useful for describing nonlinear
processes. For example, time above a critical
concentration (TACC) has been suggested as
an appropriate dose metric for the effects of
methotrexate, whose toxicity demonstrates a
strong dependence on dose rate (158). The
following discussion provides a rationale for
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Table 6. Lung tumor dose metrics.
Chloral in Lung
AUC-LADDa CMAX'
Mouse***, 600 ppmc 9.4 2.6
Mouse*, 450 ppmd 7.9 1.6
Mouse 1000 mg/kge 5.9 3.4
Mouse**, 300 ppmc 3.7 1.0
Rat, 600 ppmc 2.8(28)i 0.3(3.4)i
Mouse*, 100 ppmd 1.6 0.3
Mouse, 100 ppmc 1.2 0.3
Mouse, 50 ppmd 0.8 0.2
Human, 100 ppmf 0.016(10.5) 0.003 (2.2)
Human, 50 ppmg 0.01 (7.0Y 0.002 (1.6)
Human, 1 ppmh 0.002 (1.3) -
Human, 1 mg/Li 2 x 10-5(0.01y
`*Significantly increased lung tumors in more than one study.
`Significantly increased tumors in at least one study.
*Increased tumors in at least one study (not statistically signifi-
cant). 'Lifetime average daily area under the chloral concentra-
tion curve in the tracheebronchial region (mg/L-hr). bMaximum
concentration achieved in the tracheobronchial region (mg/L).
clnhalation, 7 hr/day, 5 days/week, 78/104 weeks (65,66).
dinhalation, 7 hr/day, 5days/week, 104weeks(64).'Oil gavage,
5 days/week, 103 weeks (65). fOccupational exposure (8 hr/day,
5days/week, 45years)-current PEL. Occupational exposure-
current TLV-TWA. hContinuous inhalation over a lifetime.
iDrinking water-lifetime continuous. iAlternate (worst-case)
calculation-see text.
the pharmacokinetic dose metrics provided
in the PBPK model and considers other
possible dose metrics that could be selected.
Liverdose metric. If, as was once thought,
reactive species produced during the metabo-
lism ofTCE were responsible for its liver car-
cinogenicity, an appropriate dose metric
would be total daily metabolism divided by
the volume of the liver (13.18). However,
current information suggests that two stable
metabolites, TCA and DCA, are primarily
responsible for the liver tumor incidence
observed in mice dosed with TCE (69,70).
The commonly accepted form of the dose
metric for the chronic interaction ofa stable
metabolite with a tissue is theAUC in the tis-
sue. This mathematical form implicitly
assumes that the cumulative effect of the
metabolite on the tissue is linear over both
concentration and time. In this case, the most
appropriate dose metricwould reflect liver tis-
sue exposure (AUC) to both TCA and DCA
(69,70). Ifit is assumed that both DCA and
TCA contribute to the carcinogenicity of
TCE in the liver, the proportion of the
observed tumor risk to assign to each metabo-
lite could be based on their relative potencies
when dosed directly. However, as mentioned
earlier, data on the AUCs for DCA resulting
from exposures to TCA [e.g., (70)] may have
been compromised by asampling artifact that
could lead to overestimates ofDCA concen-
trations in the presence ofTCA (129), mak-
ing it impossible to estimate the individual
potencies ofTCA and DCA. As asimplifying
assumption, all ofthe tumorigenicity ofTCE
can simply be ascribed to TCA, as was
assumed by Fisher and Allen (25). Since
Table 7. Kidney tumor dose metrics.
Reactive thiol in kidney
LADD(KTOX)a
Rat**, 1,000 mg/kgb 73.6
Rat, 500 mg/kgb 32.0
Rat*, 600 ppmc 19.6
Mouse, 1,000 mg/kgb 13.5
Rat, 300 ppmc 6.3
Rat, 100 ppmc 0.23
Human, 100 ppmd 0.23
Human, 50 ppme 0.09
Human, 1 ppmf 0.008
Human, 1 mg/Lg 0.0004
`Significantly increased tumors in at least one study.
*Increased tumors in at least one study (not statistically signifi-
cant). 'Lifetime average daily amount (mg) reactive metabolite
generated per gram of kidney. bOil gavage, 5 days/week, 103
weeks (67). Inhalation, 7 hr/day, 5 days/week, 78/104 weeks
(65,66). dOccupational inhalation (8 hr/day, 5 days/week, 45
years)-current PEL. 'Occupational inhalation-current
TLV-TWA. fContinuous inhalation over a lifetime. 'Drinking
water-lifetime continuous.
DCA has been detected in the mouse to a
much greater extent than in the human fol-
lowing TCE exposure, the use ofthe AUC
for TCA alone as the dose metric is almost
certainlysafe-sided (in the direction ofoveres-
timating the human risk estimate) compared
to including potency-weighted AUCs for
bothTCAand DCA.
Strictly speaking, the AUC for TCA
should actually be calculated for the concen-
tration in the liver. However, the use ofthe
AUC in the plasma provides a surrogate for
the liver AUC that can be validated more
readily against experimental data. Since risk
estimates are based on the ratio ofanimal and
human dose metrics, this effectively amounts
to an assumption that the ratios ofthe plasma
concentrations ofthe acids to their concentra-
tions in the liver are constant across species.
In fact, data on the binding ofTCA in the
plasma ofrats and humans (113) suggest that
TCA in plasma is bound to a much greater
extent in the human (- 80%) than in the
rodent (- 50%). Based on these data, it can
be estimated that the liver-to-plasma TCA
concentration ratio in the human is about
40% ofthe ratio in the rodent. This estimate
is also consistent with the ratio ofreported
relative volumes ofdistribution ofTCA in
the two species, which are on the order of 10
and 25% ofbody weight in the human and
rodent, respectively. Thus, using the AUC of
TCA in the plasma as the dose metric pro-
vides a conservative estimate of the cross-
species relationship for the AUCs in the liver,
tending to overestimate liver exposure to
TCA in the human byabout 2-fold.
Table 8 shows the predicted liver dose
metrics for the principal animal bioassays
providing a dose response for liver tumors
(59,65-67,159), for the highest rat exposures
in these same studies, and for several human
exposure scenarios. The different exposures
have been ordered according to the predicted
value ofthe LADD based on the AUC for
TCA. Bioassay exposures associated with
LADDs for AUC-TCA of greater than
1,150 were uniformly positive, whereas
bioassay exposures with LADDs less than
700 were uniformly negative. The highest
exposures of rats produced AUC-LADDs
considerably less than those producing
tumors in the mouse, consistent with the
negative results in the rat bioassays.
The most striking feature ofthe results for
this target tissue compared to the lung and
kidney is that two of the three highest dose
metrics were obtained for the human occupa-
tional exposure scenarios. The relatively high
dose metrics for AUC-TCA in the human
reflect the much slower clearance ofTCA
compared to the rodent. It is interesting to
note that the rank ordering in Table 8 would
be different ifit were based on AUC-DCA.
In that case, all ofthe human dose metrics
would be uniformly below the positive ani-
mal bioassay dose metrics, reflecting the rapid
clearance ofDCA in the human.
Although AUC is a standard metric for
tissue exposure, other forms ofthe dose met-
rics for DCAandTCA might be more appro-
priate for their modes of action. If it is
possible that the tumorigenic effects ofthese
chemicals are related to some aspect oftheir
interaction with a receptor, peak concentra-
tions (CMAX), or TACC, might actually be
more appropriate than AUCs. Another non-
linear dose metric recently discussed for
receptor-mediated effects is based on average
receptor occupancy (160). Unfortunately, the
more an attempt is made to includepharmaco-
dynamic events in a dose metric, the more
difficult it becomes to collect the data neces-
sary for its use. In the case ofTCE, there are
currently no experimental data available to
evaluate the use ofsuch alternative pharmaco-
dynamic dose metric approaches. Ofthe pos-
sible dose metrics, only AUC, CMAX, and
TACC can be estimated from the data cur-
rently available. All three ofthese metrics are
available forTCA in the PBPKmodel.
Lung dose metric. As described earlier,
tumors have been observed in the lungs of
mice exposed to TCE by inhalation. The
mechanism in this case appears to be entirely
different from that in the liver. In a well-
designed experimental effort (71), investiga-
tors at ICI combined in vivo and in vitro
experiments to elucidate the mechanism of
TCEcarcinogenicity in the mouse lung.
In the in vivo studies, female mice and
rats were exposed to TCE at a range of
inhaled concentrations at and below the
concentrations at which lung tumors have
been observed in mice, and the effects ofTCE
in the lungwere determined. Aspecific lesion,
characterized by vacuolization oflung Clara
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CMAP
TCA DCA
Human, 100 ppmc 5,490 0.26 413 0.03
Human, 50 ppmd 2,854 0.17 215 0.02
Mouse***, 600 ppme 1,748 24.0 157 5.1
Mouse***, 600 ppmf 1,488 20.8 175 5.1
Mouse**, 300 ppme 1,322 17.3 123 4.0
Mouse**, 2,339 mg/kg9 1,270 17.0 134 5.1
Mouse**, 1,739 mg/kg9 1,184 15.6 126 5.0
Mouse**, 1,000 mg/kgh 1,184 15.3 111 5.0
Mouse, 300 ppmf 1,135 15.1 138 4.0
Mouse', 1,169 mg/kg9 1,069 14.0 115 5.0
Mouse, 869 mg/kg9 986 12.6 107 4.9
Mouse**, 100 ppme 798 6.7 76 1.6
Mouse, 100 ppmf 687 5.8 86 1.6
Rat, 1,000 mg/kgh 331 3.5 23 0.4
Rat, 600 ppmf 249 2.6 23 0.4
Human, 1 ppmi 303 0.025 13 0.001
Human, 1 mg/Li 14 0.0011 0.6 5xl-5
`*Significantly increased lung tumors in more than one study. `Significantly increased tumors in at least one study. alifetime aver-
age daily area under the plasma concentration curve (mg-hr/L). bMaximum concentration achieved during exposure (mg/L).
cOccupational inhalation (8 hr/day, 5 days/week, 45years-current PEL. dOccupational inhalation-current TLV-TWA. Inhalation, 6
hr/day, 5 days/week, 104 weeks (159). Inhalation, 7 hr/day, 5 days/week, 78/104 weeks (65,66). 'Oil gavage, 5 days/week, 78/90
weeks (59). hOil gavage, 5 days/week, 103 weeks(67). ilnhalation-lifetime continuous. 'Drinking water-lifetime continuous.
cells, was observed in mice, but not rats.
There was evidence of a threshold for the
Clara cell effects at about 20 ppm. The major-
ity ofClara cells were unaffected at 20 ppm
and all enzyme markers were normal, whereas
at 200 ppm most of the Clara cells showed
marked vacuolization accompanied by marked
loss ofCYP450 activity. Mice exposed to 100
ppm CHL by inhalation displayed Clara cell
lesions similar to those observed with 1,000
ppm TCE. In contrast to these results, only
mild effects were observed with TCOH
inhaled at 100 ppm, and none were observed
with 500 mg/kg TCA given intraperitoneally.
(The effects had been observed with
intraperitoneally administered TCE at 2,000
mg/kg.) These results suggested that CHL
was responsible for the toxicity.
In the in vitro studies conducted by
Odum et al. (71), mouse lung Clara cells
metabolized TCE to CHL, TCOH, and
TCA, with CHL being the major metabolite.
Significantly, no TCOH glucuronide was
detected. In comparison with mouse Clara
cells, mouse hepatocytes produced primarily
TCOH and its glucuronide. In both cell
preparations, a steady-state concentration of
CHL was achieved. Separate in vitro studies
demonstrated that mouse Clara cells possess a
relatively low activity for the glucuronidation
of TCOH compared either to the glu-
curonidation of other substrates in the lung
or to the glucuronidation ofTCOH in the
liver. It has also been determined that ADH,
the enzyme that converts CHL to TCOH,
has low activity in the mouse lung (161),
consistent with the relatively low production
observed in the Clara cells. On the basis of
this evidence, the investigators concluded that
the observed acute toxicity in the lung was a
result ofaccumulation ofCHL in Clara cells,
resulting from a limitation in the formation
ofTCOH and its glucuronide. The speci-
ficity ofthis lesion for the Clara cells can be
rationalized in terms of their relatively high
CYP450 activity, coupled with a limited
ADH and glucuronosyltransferase activities.
The implications ofthese results for the
lung tumorigenicity ofTCE are 2-fold. First,
the accumulation ofCHL, ifit does occur in
vivo, has clear carcinogenic implications,
since CHL was genotoxic in a number of
studies (71). Second, the recurrent toxicity
observed with intermittent exposure could
produce increased cell proliferation, exacer-
bating the genotoxic effect. In terms of the
requirements for a lung dose metric in the
PBPK model ofTCE, it would appear that
the model should include, at minimum, a
description ofthe in situ metabolism ofTCE
in the Clara cell, to the extent ofproviding
dose measures based on achieved CHL con-
centrations. Although a number ofsignificant
qualitative and quantitative uncertainties
remain concerning the carcinogenicity
observed in the lung, the use of the PBPK
model could provide insights on the quantita-
tive consistency of various mechanistic
hypotheses with experimental data. There do
not appear to be sufficient data at this point
to support a quantitative description ofthe
species-dependent pharmacokinetic dose
response for the lung carcinogenicity.
The lung dose metric calculations shown
in Table 6 can be used to evaluate the consis-
tency of the CHL dose metrics with the
bioassay results. As mentioned previously, the
entries in the table are arranged in decreasing
order of LADD for AUC-CHL. Bioassay
exposures associated with LADDs for
AUC-CHL greater than 1.5 and CMAX for
CHL greater than 0.3 tended to be positive,
whereas bioassay exposures with AUC-CHL
LADDs less than 1.5 and CAMXfor CHL less
than 0.3 were uniformly negative. The daily
peak concentration dose metric (CMAX for
CHL) appears to be more consistent with the
negative response ofthe rats. Neither metric
explains the fact that the oral mouse bioassays
were negative for lung tumors, suggesting the
possibilityofaportal-of-entry effect.
Kidney dose metric. A variety ofmecha-
nisms have been identified for the kidney
effects ofhalogenated hydrocarbons (162).
The fact that tumors are observed only in the
rat might suggest that theyare associatedwith
the male rat nephropathy described for many
hydrocarbons, in which the accumulation of
a male-rat-specific a20-globulin in proximal
tubular cells leads to hyaline droplet accumu-
lation, necrosis, increased cell proliferation,
and cancer (163). However, a study designed
specifically to evaluate this possibility showed
evidence ofthe hyaline droplet accumulation
and increased cell replication with PERC but
not with TCE (163). It was also felt that the
oxidative metabolism ofTCE was unlikely to
explain the kidney carcinogenicity in rats,
since the rate of metabolism in the liver
greatly exceeds that in the kidney, and no
liver tumors are seen in the rat (72). An alter-
native mechanism was proposed, in which
direct conjugation ofTCE with GSH in the
liver was followed by further metabolism in
the kidney to a cysteine conjugate that could
then be cleaved to a reactive intermediate in
the kidney tubular cells (131). The cysteine
conjugate formed from TCE, DCVC, has
been shown to be highly nephrotoxic (78)
and mutagenic in theAmes test (115).
As with the lung carcinogenicity ofTCE,
more than one mechanism may play a role in
the kidney tumors. The tumors produced in
the kidney by TCE are very rare tumors in
control animals and do not appear to be asso-
ciated with the exacerbation ofspontaneous
processes, suggesting that a genotoxic mecha-
nism may be responsible. On the other hand,
in the onlybioassay that reported asignificant
increase in kidney tumors from TCE (67),
cytotoxicity was observed in the kidney at
both the low and high doses, whereas tumors
were observed only at the high dose. Kidney
cytotoxicity was also reported in association
with a nonstatistically significant incidence of
kidney tumors in another study (65,66).
However, dosing of mice with DCVC in
drinking water for 46 weeks produced clear
evidence oftoxicity at 87 weeks but no evi-
dence oftumors (164). The significance of
this result is enhanced by the observation that
activation ofDCVC in the kidney appears to
be much greater in the mouse than in the rat,
and the mouse also appears to be more
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responsive to the induction ofcell prolifera-
tion by DCVC than the rat (138). Moreover,
measurements of acid-labile protein adducts
in the kidney associated with DCVC suggest
that the production of DCVC-derived reac-
tive species in the kidney resulting from an
oral dose of 1,000 mg/kg TCE may actually
be greater in mice than in rats (137,138), and
mice but not rats showed increased cell prolif-
eration in the kidney in response to treatment
with TCE at 1,000 mg/kg. Other studies in
the rat also fail to support the suggestion that
significant hyperplasia is produced in the kid-
ney from exposure of rats to TCE (163).
Thus, whether a genotoxic or cytotoxic
mechanism involving DCVC is proposed, it
is difficult to explain either the negative
results ofthe DCVC bioassay in the mouse or
the greater sensitivity ofthe rat compared to
the mouse with regard to kidney tumors from
TCE. Nevertheless, a mode of action for
TCE in the kidney involving mutagenicity
and cytotoxicity from DCVC is the most
supportable choice at present, especially since
no suggestion for an alternative source ofthe
observed tumorigenicity has been provided in
any ofthe studies just described.
The kidney dose metric calculations
shown in Table 7 can be used to evaluate the
consistency of the KTOX dose metric with
the bioassay results. Bioassay exposures associ-
ated with KTOX LADDs greater than 15
tended to be positive, whereas bioassay expo-
sures with KTOX LADDs less than 15 were
negative. The mouse dose metric is well
below that ofthe rat, consistent with bioassay
results. The lower dose metric values in the
mouse result from the higher ratio ofclear-
ance (KNATC) to intoxification (KBLC) in
the mouse as compared to the rat.
Noncancer dose metrics. The issues associ-
ated with the selection ofdose metrics for the
noncancer toxicity ofTCE are discussed in a
companion article in this same issue (44).
Therefore, only a short summary of the
rationale for the selection of noncancer dose
metrics is included here. The relationship of
various noncancer dose metrics across species
is shown in Table 9. In this table, the values
of the dose metrics are shown for equal
administered dose. Clearly, the human equiv-
alent dose or concentration for a given animal
study depends on both the route ofexposure
and the dose metric chosen, which in turn
depend on the mode of action assumed for
the specific end point being considered.
Neurological effects. The neurological
effects ofshort-term exposure to solvents such
as TCE are rapidly reversible, suggesting that
they result from a physicochemical effect of
the parent chemical on the proper function of
lipophilic cellular membranes. Appropriate
dose metrics for these effects would be the
peak concentration or AUC for the parent
chemical in the brain. Since tissue-blood
partition coefficients are relatively uniform
across species, the peak concentration
in the blood can be used as a surrogate.
Alternatively, in the case ofTCE, an appro-
priate dose metric might be the peak concen-
tration for TCOH, which has been suggested
to be responsible for the observed neurological
effects ofchloral hydrate (79).
Hepatotoxicity. Pharmacokinetic studies
(73) have demonstrated that the relationship
between the acute hepatotoxicity ofTCE and
the total production of urinary metabolites is
linear, and it has been suggested that this
result is consistent with the hypothesis that
the toxicity is produced by reactive interme-
diates (13). Based on this assumption, the
most reasonable dose metric for the hepatic
toxicity ofTCE would be the total amount of
metabolism divided by the volume of the
liver (18). On the other hand, a comparison
ofthe toxic potency for TCE and PERC (73)
suggests that TCA, rather than total metabo-
lism, is responsible for the liver effects of
these chemicals (44).
Nephrotoxicity. As already discussed, the
toxicity observed in the kidney appears to be
due to metabolism of DCVC. Therefore, the
cancer dose metric (KTOX) provides a useful
metric for the kidney toxicity as well.
Immunological and developmental
effects. Significant uncertainty exists regard-
ing the appropriate dose metric for immuno-
logical and developmental effects. Possible
metrics include the peak concentrations and
AUCs for TCE and TCA. In the case offetal
effects, the dose metric would most properly
be calculated using a PBPK model with a
description ofthe fetus. However, dose met-
rics based on maternal blood should provide a
reasonable surrogate for the effects ofTCE,
since TCE and its metabolites appear to
move readily across the placenta (91).
Table 9. Noncancer daily dose metrics for continuous expos
Pharmacodynamic Dose Metrics
The discussion in this article has been
restricted primarily to pharmacokinetic issues.
However, the line between pharmacokinetics
and pharmacodynamics is ill defined, and a
pharmacokinetic model can often be
extended somewhat into the pharmacody-
namic realm. The following discussion
touches on some of the areas where there is
potential to develop improved dose metrics
for the PBPK model and that include some
level ofpharmacodynamics.
Liver. Evidence regarding the mode of
action ofTCA and DCA could potentially be
used to develop a dose metric more closely
associated with tumorigenicity. In principle,
if information on the differential response
across species to mitogenic effects from TCA
and DCA were obtained, it could be incorpo-
rated into a pharmacodynamic tissue dose
metric. Possible pharmacodynamic metrics in
the case of the liver carcinogenicity ofTCE
might be the expression ofTGF-3 or a meas-
urable suppression of cell proliferation in
hepatocytes as a marker ofan early response
to a presumed mitogenic signal. The use ofa
similar approach, based on the observed dose
dependence ofhormonal response, has been
proposed for an analogous carcinogenic
mechanism associated with follicular cell
carcinoma in the thyroid (165).
Lung andkidney. Ifthe kidney and lung
carcinogenicity ofTCE is considered to result
primarily from enhanced cell proliferation
secondary to recurrent toxicity, possible dose
metrics would include measures ofcytotoxic-
ity, cell death, or cell division, as has been
proposed for the liver carcinogenicity ofchlo-
roform (35,166). In the case ofchloroform,
fairly complicated metrics involving the
instantaneous rates ofmetabolism and distri-
butions of cellular sensitivity have been sug-
gested (5,35). To apply these approaches to
Mouse Rat Human
1 ppm inhalation
TCE, peak concentrationa 0.028 0.028 0.020
AUCb 0.77 0.80 0.56
Total metabolismc 89 79 16
TCA, peak concentration 6.9 1.0 9.7
AUC 164 24 230
TCOH, peak concentration 0.013 0.022 0.13
AUC 0.31 0.52 3.2
KTOX, production of reactive mercaptand 0.0012 0.006 0.006
1 mg/kg/day drinking water
TCE, peak concentration 0.00007 0.00048 0.009
AUC 0.0016 0.011 0.19
Total metabolism (per gram liver) 17.4 28.8 33
TCA, peak concentration 1.36 0.38 20.13
AUC 12.6 9.15 483
TCOH, peak concentration 0.0024 0.008 0.275
AUC 0.057 0.19 6.6
KTOX, production of reactive mercaptand 0.0002 0.002 0.013
"Concentration units: mg/L. bAUC unit: mg-hr/L. cTotal metabolism units: mg/kg liver. dKTOX units: mg/kg kidney.
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the kidney and lung carcinogenicity ofTCE
would require extensive studies similar to
those that have recently been conducted with
chloroform at the Chemical Industry
Institute ofToxicology (CIIT) (167-170).
Ofparticular note, the dose response for cyto-
toxicity in these subchronic studies with
chloroform is markedly different from that
observed in acute and in vitro studies (35). It
appears that caution must be used when the
dose response for a surrogate measure oftissue
response is derived from in vitro or short-term
in vivoexperiments. Ifexposure to agenotoxic
metabolite is also considered to be quantita-
tively important in the lung and kidney target
tissues, an even more complicated dose metric
would be required. The use ofa dose metric
based on the product ofDNA-protein cross-
links and cell-labeling index has been sug-
gested for evaluating the incidence ofnasal
tumors from formaldehyde exposure, assum-
ing a carcinogenic mode ofaction involving
both genotoxicity and cytotoxicity (171).
Again, extensive studies paralleling CIIT's
efforts with formaldehyde would be required
toapplythisapproach toTCE.
TargetrIsueCorrespondence
Another aspect ofuncertainty relevant to the
incorporation ofpharmacokinetic modeling in
risk assessment is the question ofhow to deal
with a lack ofcorrespondence oftarget tissues
across species. For example, none of the
tumors observed inTCEbioassays were repro-
duced in both mice and rats. This behavior
can be contrasted with that ofa trans-species
carcinogen such as vinyl chloride, which pro-
duces tumors in the same target tissue (the
liver) in all species tested, as well as in
humans, with similar potency (26). The lack
ofsite correspondence for TCE in different
animal species clearly has important implica-
tions for the expectation ofsite correspon-
dence between animals and humans (which is
implicit in the pharmacokinetic approach for
risk assessment). Nevertheless, the assumption
necessarily underlying the application ofphar-
macokinetic modeling in a risk assessment for
TCE would be that the human target tissues
ofconcern would be the same tissues identi-
fied in the animal studies. As pointed out ear-
lier, there is at least some suggestion from
epidemiological studies that another target tis-
sue for TCE in the human could be the lym-
phatic system. Ifsufficient evidence ofa link
between TCE exposure and lymphoma were
obtained from epidemiological studies, but
without sufficient dose-response information
to support a potency estimate, it is unclear
howpharmacokinetic modeling could be used
to provide an animal-based estimate unless a
statistically significant dose response for lym-
phoma could be demonstrated in the rodent.
Even then, datawould also be required on the
metabolism and mode ofaction ofTCE in
this target tissue.
HumanVariability
Standard cancer risk assessment practice
estimates the risk for an average individual,
whereas noncancer risk assessment typically
applies an uncertainty factor of 10 to account
for human variability and the possibility of
sensitive subpopulations. Human variability
plays an important role in determining the
actual risk to an individual compared to the
average risk to a population. Part ofthis vari-
ability is pharmacokinetic and is subject to
quantification. For example, the variation in
the human dose metrics forTCApresented in
Table 5 primarily reflects the impact ofvari-
ability, as opposed to uncertainty, in human
pharmacokinetics on target tissue dose (in this
case, for tissue exposure to TCA resulting
fromenvironmental exposure toTCE).
Pharmacokinetic factors affecting the
response ofan individual to the toxicity and
carcinogenicity ofa chemical such as TCE
include size, weight, condition, fat content,
and level ofphysical activity. These factors
modify the uptake, distribution, and elimina-
tion ofTCE associated with a given exposure
(172). For example, an individual with a
large proportion offat will absorb more ofa
chemical such as TCE and retain it longer
than a lean individual. This longer storage
increases the opportunity for metabolism to
the active species. Studies on normal human
volunteers have shown significant variation in
individual pharmacokinetic behavior, and it is
clear that this variability in pharmacokinetic
factors is an important component of the
overall interindividual variability ofsuscepti-
bilityto the toxiceffects ofchemicals (173).
By far the most important variability
impacting target tissue dose is in metabolism.
Four different isozymes ofCYP450 have been
found to play a role in the oxidative metabo-
lism of TCE in rodents: 1A1/2, 2B1/2,
2C1116, and 2E1. Ofthese, only 2C11/6 is
not found in humans. CYP 2E1 appears to
havethehighestaffinityforTCE, although the
other isozymes can become important at
higher concentrations (100). Sex, pregnancy,
and age-related differences in metabolism can
resultfromnormalvariations in CYP2E1 con-
tent (101); increased metabolism can result
from the inducibility ofCYP 1A1/2 (e.g., by
aromatics), 2B1 (e.g., by phenobarbital), or
2E1 (e.g., by ethanol) (102,115). Studies of
human populations have shown that the activ-
ityofthe CYP enzymes can varybymore than
a factor of 10 between individuals (152,174,
175), and that there is a genetic difference
(polymorphism) between individuals with
high activity and low activity that is associated
with a different susceptibility to cancer (176).
Genetic polymorphisms ofthe CYP enzymes
across racial and ethnic groups have been
observed (177), as have quantitative differ-
ences in metaboliccapacity (178).
Sex differences in the excretion ofTCE
metabolites have also been noted in the
human (179), with females excreting a larger
proportion ofTCA and a smaller proportion
of TCOH than males. The difference
between females and males in the ratio of
TCA to TCOH excreted is greatest initially
(as much as a factor of 5.5 during the first
24 hr after exposure), suggesting that the dif-
ference derives from arelativelygreater rate of
the production ofTCA from CHL rather
than from TCOH. The production ofTCA
in humans appears to be highly variable and
generally somewhat higher than in other ani-
mals. For example, in one study the produc-
tion ofTCA from chloral hydrate in different
individuals variedfrom 5 to47% (107).
There are still other factors such as disease
and hormonal status that could also affect the
individual risk from exposure to a TCE,
either because ofan impact on pharmacoki-
netics or metabolism, or due to other interac-
tions. Estrogens, for example, have been
associated with both increased risk (for breast
cancer) and decreased risk (for colon cancer)
and are also metabolized by the CYP system
(175). Therefore, the possibility ofinterac-
tion with TCE exposure includes metabolic
inhibition or induction as well as tumor
promotion orrepression.
Pharmacokinetic and metabolic differences
alone cannot explain the overall interindividual
variation in susceptibility observed in exposed
populations (173,180). Clearly there are other,
lesswell understood interindividual differences,
both acquired (due to environmental exposures
or disease states) and inherited (due to genetic
differences) that are also important determi-
nants ofthe individual risk for development of
toxicityfrom exposure to achemical. However,
to theextentthatwe canquantitativelydescribe
and evaluate pharmacokinetic and metabolic
variation, itwill becomeincreasinglypossible to
estimate the range ofrisks in an exposed popu-
lation and to identify the factors that put indi-
viduals atthegreatestrisk.
Conclusions
The PBPK model described in this article
provides reasonably accurate and precise esti-
mates ofdose metrics based on TCE and its
major metabolites, TCA, TCOH, and DGA,
in both experimental animals and humans.
Tissue dose metrics calculated with the
model should therefore be useful in risk
assessments for end points where the mode
ofaction involves tissue exposure to these
chemicals. Other target tissue dose metrics
that can be calculated with the model,
including CHL in the lung and DCVC in
the kidney, arehighly uncertain due to alack
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of adequate pharmacokinetic data across
species. Additional studies could greatly
reduce the uncertainty associated with these
dose metrics and make their use in risk assess-
ments more viable. However, it must be
understood that pharmacokinetics is only one
dimension of the process of estimating
human risk from animal studies; the other
potentially more important dimension is
pharmacodynamics. Species differences in
pharmacodynamics may lead to wide differ-
ences in susceptibility to tumors or to other
toxic outcomes at the same target tissue doses.
Appendix
Equations forTCEPBPKModd
Equationsfor Main (Parent Chemical)
Model
Concentration ofTCE in inhaled air(m/L):
Clnh = MWE_ xCIh(ppm) 24450.0
RateofexhalationofTCE (mg/hr):
= QPX CAB
dt PB
Concentration ofTCE in exhaled air(ppm):
CAB X24450.0
C - PB
WTCE
Rate ofchange in amount ofTCE in duo-
denum (mglhr):
IADU =ktst xAst -kaD. xADU
-ktD. XADU
Rate ofchange in amount ofTCE in gut
(mglhr):
dt QG X(CAB -CVG)+kpZm +kaSt
xAs, +kaD xAD.
Rate ofchange in amount ofTCE in liver
(mg/hr):
dALQ (C )Q
dt = % X(CAB -CVI)+Q-G
X(CVG -CVL)-RAML
-KF xCVLxVL
Rateofmetabolism in liver(mglhr):
RAML = -= VMaxL XCVL
dt I@IL +CVL
Rateofchange in amount ofTCE in stomach
(mglhr):
'= TOTAL-kast xAst -ktst xAst dtSt S St S
Rate ofchange in amount ofTCE in other
tissues (mg/hr):
dt=Q" tiQue X(CAB-CVdS,U)
Concentration ofTCE in tissue venous blood
(mg/L):
cvt.-
Rate ofexcretion ofTCE (mg/hr):
dExTCE =ktDu xADu
dt
Concentration of TCE in arterial blood
(mg/L):
C _ QCXCVB+QPXCIh AB QP QC+-
PB
Concentration of TCE in mixed venous
blood (mg/L):
QF XCVF +(QL +QG)XCVL +QSP XCV5P +QRP XCVRP
C - +QTB XCVTBQC
LiverMetabolism Submodel
Rateofchange in amount ofTCA(mg/hr):
dATCA -POX M XJ? RAML
dt MWTCE
+ MWTC xRAOXTCOH
MWTCOH
TO
-RAMTCA-kuTC xATCA
Rate ofreduction ofTCA to DCA (mg/hr):
PR/MTCA = MTCA VMaxTCA xCTCA
dt KMTCA +CTCA
Concentration ofTCA(mg/L):
CATCA CT -A
VDTCA
Rateofexcretion ofTCA(mg/hr):
dAExcTA =kuTC
X ATC
dt
4 T-
Rateofchange in amountofTCOH (mg/hr):
dATO MWTH TCOH =(1.0-PO)X TCOH XRAML
dt MWTCE
+kehrTCOH xAG! -RAOXTCOH
-RAReTCOH
-RAGITCOH
Rate ofoxidation ofTCOH to TCA(mg/hr):
RAOxTCOH = dAOXTCOH TCH dt
VMafxOTCOH X CTCOH
KAOTCOH +CTCOH
Rate ofreduction ofTCOH to DCA(mg/hr):
RAReTO = VMaxRTCOH XCTCOH
ARTCOH KMRTCOH +CTCOH
Rate ofglucuronidation ofTCOH to TCOG
(mg/hr):
RAGITCOH =VMaxGTCOH XCTCOH
IKAIGTCOH + CTCOH
Concentration ofTCOH (mg/L):
C -ATCOH CTCOH =ATH
VDTCOHU
Rate ofexcretion ofTCOH (mg/L):
dAExcTCOH - MWTCOH xkuTCOG XATCOG
dt MWTCOG
Rate ofchange in amountofTCOH (mg/hr):
dATCOG = MWTCOG xRAGITCOH
dt MWTCOH
-kehbTCOGxATCOG-kUTCOG
XATCOG
Concentration ofTCOH (mg/L):
CTCOG
= ATCOG
G
TCOH
Rate of enterohepatic recirculation of
glucuronide (mg/hr):
t =kehbTCOG xATCOG X MWTCOH
dt MWTCOG
-kehrTcOH XAGL
Rate ofchange in amount ofDCA(mg/hr):
dADCA - MWDCA xRAReTCOH +
dt MWTCOH MWTCA
XRAMTCA-RAMDCA
-kuDcA XADCA
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Rate ofdearance ofDCA (mg/hr):
RAMDCA VAIaxDCA
XCDCA
M~DCA + CDCA
Concentration ofDCA (mg/L):
.A
CDCA DAD
VDDC
WDCA
Rate ofexcretion ofDCA (mglhr):
AExcDCA = kuDCA xADCA
dt
LungMetabolism Submodel
Concentration ofTCE in tracheobronchial
venous blood (mg/L):
RAMT
CVTB =CAB
QTB
Rate ofTCE metabolism in tracheobronchi
(mg/hr):
RAMT=-dAMTB VMaxTB XCVTB
dt 'o"TB +CVTB
Concentration of chloral in Clara cells
(mg/L):
KMCTB X(~ TB IXW-
VMaXCTB MWTCE
KidneyMetabolism Submodel
Rateofchange in amount ofDCVC (mglhr):
d4DCVC = MWDCVC X AT X
CVL VL
dt MWTCE
-(knat +kbl) xADcVC
Concentration ofDCVC (mg/L):
CDO_.c ADCVC CDCVC-=
VK
Rate ofdearance ofDCVC (mg/hr):
dA=NADC MWNADC x knat x ADCVC
dt MWDCVC
DV
Kidney toxicity from DCVC (mglhr):
Irox =
t kblxADcVC
0 Vk
Variabis
Amounts
Atissue = amount ofTCE in compart-
ment (mg)
Achemical = amount ofchemical (mg)
AE.c<chemical = amount of chemical excreted
in urine (mg)
Amtissue = amount ofTCE metabolized
in compartment (mg)
AMchemical = amount ofchemical metabo-
lized(mg)
AOXTCOH = amount ofTCOH oxidized
(mg)
AReTCOH = amount ofTCOH reduced
(mg)
AglTCOH = amount ofTCOH glucuro-
nidated (mg)
Rates
RAMtissue = rate of metabolism of TCE in
compartment (mg)
RAMchemical = rate of metabolism of chemi-
cal (mg)
RAOXTCOH = rate ofoxidation ofTCOH
(mg)
RAReTCOH = rate of reduction ofTCOH
(mg)
RAGITCOH = amount ofglucuronidation of
TCOH (mg)
Concentrations
Ctissue = concentration of TCE in
compartment (mg/L)
Cchemica = concentration of chemical
(mg/L)
CVtissue = venous concentration ofTCE
in compartment (mg/L)
Parameters
Flow rates
QC
Q£issue
QP
Volumes
Vtissue
VDchemical
Partitions
PB
Ptissue
Rate constan
= cardiac output (L/hr)
= blood flow to compartment
(L/hr)
= pulmonaryventilation (LIhr)
= volume ofcompartment (kg)
= volume of distribution for
chemical (kg)
= blood to air partition coeffi-
cient
= tissue to blood partition coef-
ficient
Its
katiue = oral uptake rate from com-
partment (/hr)
kehbTcOG = biliary excretion rate of
TCOG (Ihr)
kehrTcoH = enterohepatic recirculation
rate forTCOH (/hr)
kpZero = input rate for TCE in drink-
ing water (mg/hr)
kttissue = transfer rate from compart-
ment (/hr)
kuchemica = urinary excretion rate of
chemical (/hr)
Parameters (cont'd)
Metabolism parameters
PO = percent oxidation ofchloral
KF = rate ofproduction ofDCVC
fromTCE (/hr)
kbl = rate ofmetabolism ofCDVC
byP-lyase (/hr)
knat = clearance rate of DCVC by
NAT (/hr)
Vmaxtissue = capacity for metabolism of
TCE in compartment (mg/hr)
VMaxCtissue = capacity for chloral clearance
in compartment (mg/hr)
VMaxchemical = capacity for metabolism of
chemical (mg/hr)
VMarGrCOH= capacity for glucuronidation
ofTCOH (mg/hr)
VMaxTCOH= capacity for oxidation of
TCOH (mg/hr)
VMaxRTCOH = capacity for reduction of
TCOH (mg/hr)
Kmtissue = affinity for metabolism of
TCE in compartment (mg/L)
KMCudssue = affinityforchloral clearance in
compartment (mg/L)
KMchemica1 = affinity for metabolism of
chemical (mg/L)
KMGTCOH = affinity for glucuronidation of
TCOH (mg/L)
KMOTCOH = affinity for oxidation of
TCOH (mg/L)
KMRTCOH = affinity for reduction of
TCOH (mg/L)
Other
KTox = metric for kidney cytotoxicity
from DCVC
MWchemical = molecular weight ofchemical
(mg/mole)
TOTAL = total oral dose ofTCE (mg)
Compartments (denotedby "tissue'"
AB = arterial blood
Du = duodenum
Exh = exhaled air
F = fat
G = gut tissue
GL = gut lumen
Inh = inhaled air
L = liver
RP = rapidlyperfused tissues
SP = slowlyperfused tissues
St = stomach
TB = tracheo-bronchi
VB = venous blood
Chemicals (denotedby "chemical')
Chl
DCA
DCVC
NADC
TCA
TCE
TCOG
TCOH
= chloral
= dicloroacetic acid
= dichlorovinylcysteine
= N-acetyl-DCVC
= trichloroacetic acid
= trichlorethylene
= TCOH glucuronide
= trichloroethanol
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